



UMP HEALTHCARE HOLDINGS LIMITED
聯合醫務集團有限公司

(Stock Code 股份代號: 722)

(Incorporated in the Cayman Islands with limited liability
於開曼群島註冊成立之有限公司)



INTERIM REPORT
2021/2022
中期報告



CONTENTS

目錄

- | | | | |
|----|--------------------------------------------------------------------------|----|----------------------------------------------------------------------------------------|
| 2 | Corporate Information
公司資料 | 35 | Condensed Consolidated Statement
of Financial Position
簡明綜合財務狀況表 |
| 4 | Management Discussion and
Analysis
管理層討論及分析 | 37 | Condensed Consolidated Statement
of Changes in Equity
簡明綜合權益變動表 |
| 19 | Corporate Governance Highlights
企業管治摘要 | 38 | Condensed Consolidated Statement
of Cash Flows
簡明綜合現金流量表 |
| 21 | Other Information
其他資料 | 40 | Notes to the Condensed
Consolidated Interim Financial
Statements
簡明綜合中期財務報表附註 |
| 33 | Condensed Consolidated Statement
of Profit or Loss
簡明綜合損益表 | 71 | Glossary
詞彙 |
| 34 | Condensed Consolidated Statement
of Comprehensive Income
簡明綜合全面收入表 | | |

Corporate Information

公司資料

BOARD OF DIRECTORS

Executive Directors

Dr. Sun Yiu Kwong (*Chairman and Chief Executive Officer*)
Ms. Kwok Cheuk Kwan, Jacquen (*Managing Director*)
Mr. Tsang On Yip, Patrick
Dr. Sun Man Kin, Michael
Mr. Lee Kar Chung, Felix
Dr. Lee Pak Cheung, Patrick

Independent Non-executive Directors

Mr. Lee Luen Wai, John *BBS JP*
Dr. Li Kwok Tung, Donald *SBS JP*
Mr. Yeung Wing Sun, Mike
Mr. Chau, Chit Jeremy

AUDIT COMMITTEE

Mr. Lee Luen Wai, John *BBS JP* (*Chairman*)
Dr. Li Kwok Tung, Donald *SBS JP*
Mr. Yeung Wing Sun, Mike

REMUNERATION COMMITTEE

Dr. Li Kwok Tung, Donald *SBS JP* (*Chairman*)
Mr. Yeung Wing Sun, Mike
Mr. Tsang On Yip, Patrick

NOMINATION COMMITTEE

Dr. Sun Yiu Kwong (*Chairman*)
Mr. Lee Luen Wai, John *BBS JP*
Dr. Li Kwok Tung, Donald *SBS JP*

AUTHORISED REPRESENTATIVES

Mr. Lee Kar Chung, Felix
Mr. Au, In Kee Adam

COMPANY SECRETARY

Mr. Au, In Kee Adam

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS

27th Floor
Wing On House
71 Des Voeux Road Central
Hong Kong

董事會

執行董事

孫耀江醫生 (*主席兼行政總裁*)
郭卓君女士 (*董事總經理*)
曾安業先生
孫文堅醫生
李家聰先生
李柏祥醫生

獨立非執行董事

李聯偉先生 (*銅紫荊星章·太平紳士*)
李國棟醫生 (*銀紫荊星章·太平紳士*)
楊榮樂先生
周哲先生

審核委員會

李聯偉先生 (*銅紫荊星章·太平紳士*) (*主席*)
李國棟醫生 (*銀紫荊星章·太平紳士*)
楊榮樂先生

薪酬委員會

李國棟醫生 (*銀紫荊星章·太平紳士*) (*主席*)
楊榮樂先生
曾安業先生

提名委員會

孫耀江醫生 (*主席*)
李聯偉先生 (*銅紫荊星章·太平紳士*)
李國棟醫生 (*銀紫荊星章·太平紳士*)

授權代表

李家聰先生
歐衍基先生

公司秘書

歐衍基先生

總部及主要營業地點

香港
中環德輔道中71號
永安集團大廈
27樓

REGISTERED OFFICE

Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS

Conyers Trust Company (Cayman) Limited
Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR

Tricor Investor Services Limited
Level 54
Hopewell Centre
183 Queen's Road East
Hong Kong

AUDITOR

KPMG
Public Interested Entity Auditor registered in
accordance with the Financial Reporting Council Ordinance
8th Floor, Prince's Building
10 Charter Road
Central, Hong Kong

LEGAL ADVISER

Allen & Overy
9th Floor, Three Exchange Square
Central, Hong Kong

PRINCIPAL BANKER

Hang Seng Bank Limited
20th Floor
83 Des Voeux Road Central
Hong Kong

STOCK CODE

722

COMPANY WEBSITE

www.ump.com.hk

註冊辦事處

Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

開曼群島主要股份過戶登記處

Conyers Trust Company (Cayman) Limited
Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

香港股份過戶登記分處

卓佳證券登記有限公司
香港
皇后大道東183號
合和中心
54樓

核數師

畢馬威會計師事務所
《財務匯報局條例》下的
註冊公眾利益實體核數師
香港中環
遮打道十號
太子大廈八樓

法律顧問

安理國際律師事務所
香港中環
交易廣場三座九樓

主要往來銀行

恒生銀行有限公司
香港
中環德輔道中83號
20樓

股份代號

722

公司網站

www.ump.com.hk

Management Discussion and Analysis

管理層討論及分析

BUSINESS OVERVIEW AND OUTLOOK

As the COVID-19 pandemic continues to exert an unprecedented impact on the whole healthcare industry and our business, our Group has demonstrated its resilience to serve our stakeholders and communities with the uninterrupted provision of professional and trusted healthcare services.

Our disciplined operating culture and the advantage of our enterprise capabilities significantly contributed to the promising results for the Group over the past six months. In addition, every corner of our organization came together to uphold our mission and do what is suitable for our patients, colleagues, and healthcare practitioners.

Despite the continued operational headwind induced by the pandemic, we remain confident in the market outlook. In July 2021, we expanded our flagship medical centre at Wing On House in Central to two floors, with a gross floor area of approximately 27,000 sq. ft.. The new medical centres comprise a full spectrum of medical and dedicated specialist services, including the Group's first cardiometabolic centre, first UMP-branded physiotherapy and rehabilitation centre, and a newly-extended specialist centre featuring elderly care, diabetes and chronic disease management, as well as preventive cardiology. This one-stop medical care ecosystem caters for the needs of the B2B as well as the up-and-coming B2B2C market, particularly in the Central district, and pushes profitability while creating value for society and ensuring sustainability is observed.

This refreshed strategic approach demonstrates our confidence in our business model and adaptability during the pandemic. We have relocated our headquarter office to a newly-leased floor. The new office space allows us to group our frontline and back office in the same building to provide immediate support to our clinical services. Further, our servicing facilities in the flagship centre have undergone expansion and renovation to ensure they meet the changing needs of the communities. As a result, clients and patients benefit from enhanced access to our services with a welcoming and contemporary space.

業務回顧及展望

新型冠狀病毒疫情繼續對整個醫療行業以至我們的業務造成前所未見的影響之際，本集團在逆境中盡展韌勁，持續不竭地為持份者和社區提供值得信賴的專業醫療保健服務。

我們規律有序的經營文化及以企業實力構建的優勢，為本集團在過去六個月的佳績作出重要貢獻。此外，集團上下一心，堅守使命，因時制宜為患者、同事和醫療工作者提供適切服務。

儘管疫情依舊對營運造成挑戰，但我們對市場前景依然充滿信心。於2021年7月，我們將位於中環永安集團大廈的旗艦醫務中心擴充至兩層，總樓面面積達約27,000平方呎。新醫務中心提供全面的醫療和專科醫療服務，包括本集團首個心血管代謝中心、首個以聯合醫務為名的物理治療及復康中心，以及提供長者護理、糖尿病及慢性疾病管理以及預防性心臟科等相關服務的新擴建專科中心。這個一站式醫療生態體系滿足了B2B以及方興未艾的B2B2C市場(尤其是在中區)的需要，為社會創造價值及確保可持續發展的同時，亦有助提高集團的盈利能力。

此項全新策略方針印證我們對本身商業模式的信心，以及在疫情期間的應變能力。我們將總部辦公室遷至永安集團大廈新租樓層。新的辦公室讓我們的前線和後勤辦公室匯聚在同一大樓內，為我們的臨床醫療服務提供即時支援。此外，我們在旗艦中心的服務設施已完成擴建和翻新，確保相關設施滿足社區不斷變化的需要。客戶和患者現可在舒適而時尚的空間內獲得更多元化服務。

Management Discussion and Analysis 管理層討論及分析

Besides our flagship centre, our well-established multi-specialties clinic network provides convenient, reliable, coordinated, comprehensive and affordable healthcare services. As of 31 December 2021, our network consisted of more than 1,100 self-owned and affiliated service points of medical disciplines located across Hong Kong and Macau. In addition, as part of our growth strategy, we continue to expand our offline clinical services coverage in areas with rapid population growth.

Our clinic network touches millions of lives each year by providing actionable health insights to patients and doctors. Our clinic network's quality, depth, and scope are essential to ensure trusted and affordable healthcare services to an inclusive clientele. By partnering with quality, cost-effective providers, we utilize our clinical and operational know-how derived from our medical history and expertise to gain insight into the rising needs of both our members and our providers. To support our expansion and development, we have also expanded our own professional medical team and recruited additional medical experts in specialties, such as family medicine, internal medicine, geriatric care, radiology, imaging and laboratory.

Advanced medical imaging and laboratory services continue to form an integral part of our business. Rising demand for diagnostic imaging, such as Positron Emission Tomography (PET scan), Magnetic Resonance Imaging (MRI), Computerized Tomography (CT scan), Ultrasound, Mammography and X-ray has driven significant growth for our Group stemming from the growing ageing population as well as the rising health awareness among the population.

Apart from medical and diagnostic demands, the ageing population and a greater focus on early detection and preventive medicine are anticipated to support our Group's performance in the coming years. The rise in public health consciousness has also led to the increase in average spending of the medical segment. More household budget is now allocated to health assessment and related preventive medical services.

除了我們的旗艦中心，我們完善的網絡包含多個不同專科，亦提供便捷、可靠、協調、全面及實惠的醫療保健服務。截至2021年12月31日，我們的網絡覆蓋1,100多個自營及附屬醫療保健服務點，遍佈香港及澳門。此外，作為我們增長策略的一環，我們繼續在人口快速增長區域擴大集團線下臨床醫療服務覆蓋面。

我們的診所網絡通過為患者和醫生提供可行的健康見解，每年觸及數以百萬計的生命。我們診所網絡的質素、深度和範圍，是為廣大客戶提供值得信賴和可負擔的醫療保健服務之關鍵。我們善用從自身的醫療業務營運路上所積累的臨床和營運知識以及專業訣竅，通過夥拍具成本效益之優秀機構合作，掌握我們的成員和供應商不斷增長的需要。為支持我們的擴張及發展，我們亦已壯大本身的專業醫療團隊，並在家庭醫學、內科、長者護理、放射科、醫學影像及化驗室等專業領域增聘更多醫療專家。

先進醫療影像及化驗室服務繼續是旗下業務不可或缺的一環。在年長年齡組別人口持續增長以及更為關注健康的趨勢下，正電子發射斷層掃描（PET掃描）、磁力共振成像（MRI）、電腦斷層掃描（CT掃描）、超聲波、乳房X光檢查和X光等診斷影像的需求不斷上升，推動本集團此方面的收入大幅增長。

除了醫療及診斷需求之外，人口老齡化及對早期檢測和預防醫學的更多關注，預計將支持本集團於未來年度的表現。公眾日益關注健康亦帶動醫療方面的平均支出增加。現時一般家庭預算中，健康評估及相關的預防性醫療服務比重亦見上升。

Management Discussion and Analysis 管理層討論及分析

Further, we see rapid growth of demand and offer one-stop health assessment services at our designated medical centres. We provide a full range of health assessment services holistically, including those designed specifically for different groups and common health problems to cater for different needs, along with COVID-related assessments and examinations for immigration visa requirements.

To back our growing business in the digital era, we believe technology is an essential enabler of medical services provision improvement. Leveraging digital technologies to provide efficient and affordable medical services will play a huge role in the success of our expansion. Our digital strategy, supported by a strong team of IT experts, centred around satisfying the demands of patients and our physicians.

Besides the ongoing effort to streamline and digitalize our patient journey and data management for clinic operations efficiency, we have been actively seeking collaboration with third-party service providers to augment the quality of our services and to add value to the standard of patient care. While we pursue open innovation to bring revenue streams and business lines, we insist that cybersecurity and digital inclusion for all demographics as the priorities in our digital strategy.

Due to the continued impact of the pandemic and the rise of Omicron variant infection, we expect the operating environment remains challenging in the coming future. Nevertheless, rising healthcare awareness and demand will usher in a more tech-and patient-centric healthcare industry. Alongside, we are confident that Hong Kong and Macau will continually be preferred destinations for medical-services travel in a post-pandemic era for nearby areas, with relative cost competitiveness and the availability of skilled medical professionals.

此外，有見健康評估的需求快速增長，我們在旗下指定的醫務中心提供一站式的全方位健康評估服務，包括專門為不同組別和常見健康問題而設的服務，以滿足不同需要，同時亦設有新型冠狀病毒相關評估及有關移民簽證要求的檢查。

為支持旗下不斷增長的業務在數碼時代之進一步發展，我們相信科技是提供更完善醫療服務的關鍵。利用數碼技術提供高效和可負擔的醫療服務，將對我們的成功擴張起著重大作用。在強大的資訊科技專家團隊作後盾下，我們的數碼策略聚焦於滿足患者及醫生之需要。

我們不斷努力精簡患者的求診歷程並將之數碼化，以及推動數據管理以提高診所的營運效率。除此以外，我們亦一直積極尋求與第三方服務供應商合作，以提高我們的服務質素，並為患者護理服務之標準增值。在我們追求開放創新以帶來收入流和業務線的同時，我們的數碼策略始終以網絡安全及數碼共融為優先要務。

由於疫情之影響持續，加上感染Omicron變異株的個案上升，我們預計未來的經營環境仍然充滿挑戰。然而，大眾的健康意識提高和與日俱增的需求，將令未來的醫療保健行業更加著重科技的應用並且以患者為先。同時，我們有信心，在後疫情時代，憑藉相對的成本競爭力和熟練的醫療專才，香港及澳門將繼續是鄰近地區之首選醫療服務旅遊目的地。

Management Discussion and Analysis

管理層討論及分析

To ensure our business is more financially sustainable and future-ready, we have repositioned our presence in the PRC and reorganized our emerging business in Mainland China with the disposal of an indirectly owned subsidiary, UMP Healthcare China, in December 2021. We retain a significant strategic stake in the said business, and continue to operate conventional clinical and healthcare check-up business conducted by the clinics that we own and operate in Beijing and Shanghai. We will continue to seek growth opportunities in the Greater Bay Area in the coming future.

Overall, we maintain focus on our core business of corporate health solutions and clinical and IME services in Hong Kong, Macau and Mainland China. We actively expand our business through acquisition and opening new business units targeting new market frontiers.

Underlying our accomplishments are our dedicated team members who continue to provide outstanding and compassionate care during this extraordinary time. We will remain resolute to focus on delivering quality healthcare services and maximizing our growth potential with the mission of enabling better health for everyone.

OUR BUSINESS LINES AND THEIR ANALYSIS

UMP's business scope consists of the following business lines:

Hong Kong & Macau Corporate Healthcare Solution Services

UMP provides corporate healthcare solutions through the design and administration of tailored healthcare benefits plans for its Contract Customers. The Group's Contract Customers comprise (i) insurance companies, who enter into contracts with the Group for healthcare services for their policyholders or employees of their policyholders and (ii) corporations, who enter into contracts with the Group for healthcare services for their employees and/or their dependants. When designing healthcare benefits plans, the Group collaborates closely with the Contract Customers to design and refine corporate healthcare benefits plans, with each plan tailored to the customer's needs based on factors such as industry or occupational health-related concerns, the scope of healthcare benefits desired, employee demographic as well as their budget.

為了確保旗下業務在財務上更能支持集團之可持續發展，並為未來作好準備，我們對中國業務進行重新定位，於2021年12月出售間接擁有的附屬公司聯合醫務中國，藉此重組在中國內地的新興業務。我們仍然在上述業務持有重要的策略股權，並繼續在我們於北京及上海擁有及經營之診所經營傳統臨床及體檢業務。我們於未來將繼續物色大灣區的增長機遇。

總括而言，我們將繼續專注於我們在香港、澳門及中國內地的企業醫療保健解決方案以及臨床和IME服務的核心業務。我們通過收購及開設專攻新冒起的市場之新業務單位而積極拓展業務。

我們今天取得的種種成就，全賴每一位團隊成員敬業樂業，在這段非常時期仍能將心比己，繼續提供出色的醫護服務。我們將繼續專注於提供優質的品牌醫療服務，全力發揮增長潛力，履行讓大眾更健康的使命。

我們的業務線及其分析

聯合醫務的業務範疇包括以下業務線：

香港及澳門企業醫療保健解決方案服務

聯合醫務通過設計及管理針對其合約客戶度身定製的醫療保健福利計劃，提供企業醫療保健解決方案。本集團的合約客戶包括(i)保險公司，為彼等保單持有人或保單持有人的僱員就醫療保健服務與本集團訂立合約；及(ii)企業，為彼等僱員及／或彼等之受養人就醫療保健服務與本集團訂立合約。在設計醫療保健福利計劃時，本集團與合約客戶密切合作，設計及優化企業醫療保健福利計劃，根據行業或有關的職業健康問題、所需醫療福利的範圍、僱員特徵及其預算開支等因素，針對每一客戶的需求提供度身定製的計劃。

Management Discussion and Analysis 管理層討論及分析

UMP aims to provide convenient, reliable, coordinated, comprehensive and affordable healthcare services through our well-established and multi-specialties UMP Network. As of 31 December 2021, the UMP Network comprises more than 1,100 points of services located across Hong Kong and Macau.

Revenue for this business line has slightly increased by 1.8% from HK\$122.3 million to HK\$124.5 million (before inter-segment elimination). However, our operating profit (operating profit before tax and before non-recurring items) has decreased by 41.2% from HK\$33.0 million to HK\$19.4 million. The results are primarily due to the patient visits last year being severely impacted by COVID-19.

Hong Kong & Macau Clinical Healthcare Services

UMP provides medical, dental and auxiliary services to Self-paid Patients. For medical services, UMP provides (i) general practice services, which serves as the first point of contact for the patients and (ii) specialist services covering more than 16 different specialties. For dental services, UMP provides both primary dental care and secondary dental care such as dental implants. For auxiliary services, UMP provides services such as medical imaging and laboratory services, physiotherapy and vision care.

Revenue for this business line has increased by 28.1% from HK\$213.1 million to HK\$273.0 million (before inter-segment elimination) and our operating profit (operating profit before tax and before non-recurring items) has increased 33.2% from HK\$38.9 million to HK\$51.8 million. This increase is due to a general increase in the number of health check-ups and contributions from our medical imaging and laboratory business.

聯合醫務旨在通過完善及多個不同專科的UMP網絡，提供便捷、可靠、協調、全面及實惠的醫療保健服務。於2021年12月31日，UMP網絡包括超過1,100個位於香港及澳門的服務點。

來自此業務線的收入由122.3百萬港元略增1.8%至124.5百萬港元（分部間抵銷前）。然而，我們的經營利潤（除稅前及除非經常性項目前經營利潤）由33.0百萬港元減少41.2%至19.4百萬港元。此業績主要由於去年的患者就診次數受2019冠狀病毒病嚴重影響所致。

香港及澳門臨床醫療保健服務

聯合醫務向自費患者提供醫療、牙科及輔助服務。醫療服務方面，聯合醫務提供(i)全科醫療服務，為患者的首個接觸點；及(ii)專科服務，覆蓋超過16個不同專科。牙科服務方面，聯合醫務提供基本牙科護理及第二層牙科護理（例如植牙）。輔助服務方面，聯合醫務提供醫學影像及化驗服務、物理治療以及眼科護理等服務。

來自此業務線的收入由213.1百萬港元增加28.1%至273.0百萬港元（分部間抵銷前），而我們的經營利潤（除稅前及除非經常性項目前經營利潤）由38.9百萬港元增加33.2%至51.8百萬港元。增加乃主要得力於提供的體檢次數整體增加以及醫學影像及化驗室業務的貢獻。

Management Discussion and Analysis

管理層討論及分析

Mainland China Clinical Healthcare Business

Our Mainland China clinical healthcare business currently consists of (i) health check-up business and (ii) selected outpatient services such as family medicine within the clinics we own and operate. Revenue for this business line has increased by 29.9% from HK\$17.5 million to HK\$22.7 million (before inter-segment elimination) due to an increase in the number of health check-ups, while our operating result has improved from operating loss (operating loss before tax and before non-recurring items) of HK\$8.2 million to operating profit (operating profit before tax and before non-recurring items) of HK\$0.5 million.

Discontinued Operation

The Group engaged in (i) corporate healthcare solutions business (online merged to offline) and (ii) provision of professional training to doctors and nurses under our GOLD™ training programme in Mainland China by the subsidiaries of UMP Healthcare China Limited (“UMP Healthcare China”), a non-wholly owned subsidiary indirectly owned as to 80% by the Company. On 31 December 2021, 55% shareholding of UMP Healthcare China was disposed of at a consideration of HK\$22 million. Subsequent to the transaction, the Group’s shareholding in UMP Healthcare China decreased from 80% to 25%, and the Group ceased control over UMP Healthcare China. As a result, UMP Healthcare China and its subsidiaries have become the associates of the Group. Please refer to the announcement dated 22 December 2021 for further details.

Prior to the completion of disposal, revenue for this business line has increased by 108.7% from HK\$2.9 million to HK\$6.1 million (before inter-segment elimination) due to an increase in income from our training business and online medical services, while the operating loss (operating loss before tax and before non-recurring items) has decreased by 2.1% from HK\$14.5 million to HK\$14.2 million.

中國內地臨床醫療保健業務

我們的中國內地臨床醫療保健業務目前專注於(i)體檢業務；及(ii)在我們擁有及營運的診所內提供選定門診服務(如家庭醫學)。由於提供的體檢次數增加，來自此業務線的收入由17.5百萬港元增加29.9%至22.7百萬港元(分部間抵銷前)，而我們的經營業績則由8.2百萬港元的經營虧損(除稅前及除非經常性項目前經營虧損)改善至0.5百萬港元的經營利潤(除稅前及除非經常性項目前經營利潤)。

已終止經營業務

我們過去透過本公司間接擁有80%權益之非全資附屬公司聯合醫務中國有限公司(「聯合醫務中國」)的附屬公司在中國內地從事(i)企業醫療保健解決方案業務(線上合併至線下)及(ii)根據我們的GOLD™金牌培訓課程向醫生及護士提供專業培訓。於2021年12月31日，聯合醫務中國的55%股權以22百萬港元的代價出售。交易完成後，本集團在聯合醫務中國的持股比例從80%降至25%而本集團不再控制聯合醫務中國。因此，聯合醫務中國及其附屬公司已成為本集團的聯營公司。進一步詳情請參閱日期為2021年12月22日的公告。

於出售完成前，此項業務的收入因培訓業務及網上醫療服務之收入增加而由2.9百萬港元增加108.7%至6.1百萬港元(分部間抵銷前)，而經營虧損(除稅前及除非經常性項目前經營虧損)則由14.5百萬港元減少2.1%至14.2百萬港元。

Management Discussion and Analysis 管理層討論及分析

The following table sets out the revenue for our business lines for the six months ended 31 December 2021 and the corresponding period for comparison:

下表載列我們截至2021年12月31日止六個月以及相應期間的業務線收入以供比較：

Revenue by business lines

按業務線劃分收入

		Six months ended 31 December 截至12月31日止六個月		Increase/ (decrease)
		2021 2021年 HK\$'000 千港元	2020 2020年 HK\$'000 千港元	增加/ (減少)
Hong Kong & Macau Corporate Healthcare Solution Services	香港及澳門企業醫療 保健解決方案服務	124,490	122,275	1.8%
Hong Kong & Macau Clinical Healthcare Services	香港及澳門臨床醫療 保健服務	272,987	213,054	28.1%
Mainland China Clinical Healthcare Business	中國內地臨床醫療 保健業務	22,705	17,484	29.9%
Total revenue from continuing operations	來自持續經營業務的 總收入	420,182	352,813	19.1%
Discontinued Operation	已終止經營業務	6,099	2,922	108.7%
TOTAL	合計	426,281	355,735	19.8%

(1) Business lines revenue presented above are before inter-segment sales elimination.

(1) 上表所呈列業務線收入為進行分部間銷售抵銷前。

Management Discussion and Analysis

管理層討論及分析

FINANCIAL REVIEWS

1HFY2022 compared to 1HFY2021

Revenue from Continuing Operations

During 1HFY2022, we primarily generated revenue from (i) the provision of corporate healthcare solutions to Contract Customers in Hong Kong and Macau; (ii) the provision of clinical healthcare services in Hong Kong and Macau and (iii) the provision of clinical healthcare services in Mainland China.

Total consolidated revenue from continuing operations increased by 19.7% from HK\$299.2 million in 1HFY2021 to HK\$358.2 million in 1HFY2022, primarily due to general increase in number of health check-ups and contribution from our medical imaging and laboratory business.

Provision of corporate healthcare solution services to Contract Customers in Hong Kong and Macau

Revenue from the provision of corporate healthcare solution services to Contract Customers in Hong Kong and Macau increased by 1.6% from HK\$121.6 million for 1HFY2021 to HK\$123.5 million for 1HFY2022.

- **Medical.** Revenue generated from the provision of Medical Services to Contract Customers increased by 2.4% from HK\$109.8 million for 1HFY2021 to HK\$112.4 million for 1HFY2022, primarily due to an increase in the number of visits from patients seeking Medical Services.
- **Dental.** Revenue generated from the provision of Dental Services to Contract Customers decreased by 6.1% from HK\$11.8 million for 1HFY2021 to HK\$11.1 million for 1HFY2022, primarily due to a decrease in patients' average spending per visit for seeking Dental Services.

Provision of clinical healthcare services in Hong Kong and Macau

- **Medical.** Revenue generated from the provision of Medical Services to Self-paid Patients increased by 36.9% from HK\$132.7 million for 1HFY2021 to HK\$181.6 million for 1HFY2022, primarily due to general increase in number of health check-ups and contribution from our medical imaging and laboratory business.

財務回顧

2022財政年度上半年與2021財政年度上半年比較

來自持續經營業務的收入

於2022財政年度上半年，我們的收入主要產生自(i)於香港及澳門向合約客戶提供企業醫療保健解決方案；(ii)於香港及澳門提供臨床醫療保健服務及(iii)於中國內地提供臨床醫療保健服務。

來自持續經營業務的總綜合收入由2021財政年度上半年299.2百萬港元增加19.7%至2022財政年度上半年358.2百萬港元，乃主要得力於提供的體檢次數整體增加以及醫療影像及化驗室業務的貢獻。

於香港及澳門向合約客戶提供企業醫療保健解決方案服務

來自向香港及澳門的合約客戶提供企業醫療保健解決方案服務的收入由2021財政年度上半年121.6百萬港元增加1.6%至2022財政年度上半年123.5百萬港元。

- **醫療。**向合約客戶提供醫療服務的收入由2021財政年度上半年109.8百萬港元增加2.4%至2022財政年度上半年112.4百萬港元，乃主要由於尋求醫療服務的患者就診次數增加。
- **牙科。**向合約客戶提供牙科服務的收入由2021財政年度上半年11.8百萬港元減少6.1%至2022財政年度上半年11.1百萬港元，乃主要由於尋求牙科服務患者的次均就診開支減少。

於香港及澳門提供臨床醫療保健服務

- **醫療。**向自費患者提供醫療服務的收入由2021財政年度上半年132.7百萬港元增加36.9%至2022財政年度上半年181.6百萬港元，乃主要得力於提供體檢次數整體增加以及醫療影像及化驗室業務的貢獻。

Management Discussion and Analysis

管理層討論及分析

- **Dental.** Revenue generated from the provision of Dental Services to Self-paid Patients increased by approximately 10.8% from HK\$27.5 million for 1HFY2021 to HK\$30.4 million for 1HFY2022 due to the increase in number of self-paid patient visits.

Mainland China Clinical Healthcare Business

Revenue generated from Mainland China clinical healthcare business increased by 29.9% from HK\$17.5 million for 1HFY2021 to HK\$22.7 million for 1HFY2022, primarily due to an increase in the number of health check-ups.

Other Income and Gains

Other income and gains primarily comprise administrative support fees (including fees derived from providing administrative support to Affiliated Doctors, Affiliated Dentists and Affiliated Auxiliary Services Providers), bank interest income, interest income from financial assets at amortised cost, dividend and interest income from investments at fair value through other comprehensive income and investments at fair value through profit or loss, gain on disposal of subsidiaries and fixed assets, and other income.

Other income and gains increased by 11.6% from HK\$3.8 million for 1HFY2021 to HK\$4.3 million for 1HFY2022.

Professional Services Expenses

Professional services expenses primarily comprise fees paid to Doctors, Dentists and Auxiliary Services Providers for Medical Services, Dental Services and Auxiliary Services rendered within the UMP Network, as well as fees paid to third party laboratories and testing centres for services rendered to the Group.

Professional services expenses increased by 16.1% from HK\$109.7 million for 1HFY2021 to HK\$127.3 million for 1HFY2022, primarily due to an increase in the cost of services rendered by doctors, dentists and other professionals.

Property Rental and Related Expenses

Property rental and related expenses increased by 18.5% from HK\$3.9 million for 1HFY2021 to HK\$4.6 million for 1HFY2022, primarily due to the rental concessions granted by landlords of various premises in 1HFY2021, which did not recur in 1HFY2022.

- **牙科。**向自費患者提供牙科服務的收入由2021財政年度上半年27.5百萬港元增加約10.8%至2022財政年度上半年30.4百萬港元，乃主要由於自費患者就診次數增加。

中國內地臨床醫療保健業務

來自中國內地臨床醫療保健業務的收入由2021財政年度上半年17.5百萬港元增加29.9%至2022財政年度上半年22.7百萬港元，乃主要由於體檢次數增加。

其他收入及收益

其他收入及收益主要包括行政支援費用（包括向聯屬醫生、聯屬牙醫及聯屬輔助服務提供者提供行政支援所產生的費用）、銀行利息收入、按攤銷成本計量的金融資產的利息收入、按公允價值計入其他全面收入的投資以及按公允價值計入損益的投資之股息及利息收入、出售附屬公司及固定資產之收益，以及其他收入。

其他收入及收益由2021財政年度上半年3.8百萬港元增加11.6%至2022財政年度上半年4.3百萬港元。

專業服務費用

專業服務費用主要包括就醫生、牙醫及輔助服務提供者於UMP網絡內提供的醫療服務、牙科服務及輔助服務向其支付的費用，以及就第三方化驗及檢測中心向本集團提供的服務而支付的費用。

專業服務費用由2021財政年度上半年109.7百萬港元增加16.1%至2022財政年度上半年127.3百萬港元，主要由於醫生、牙醫及其他專業人士提供服務的成本增加。

物業租金及相關開支

物業租金及相關開支由2021財政年度上半年3.9百萬港元增加18.5%至2022財政年度上半年4.6百萬港元，主要由於不同處所的業主於2021財政年度上半年給予租金減免而此情況並無在2022財政年度上半年重現。

Management Discussion and Analysis

管理層討論及分析

Depreciation and Amortisation

Depreciation and amortisation, which comprises of depreciation of the right-of-use assets and depreciation and amortisation of other non-current assets, remained stable in 1HFY2022 when compared with 1HFY2021.

Other Expenses, net

Other expenses, net primarily comprise provision of impairment loss, general overhead expenses such as utilities, operation and other administrative expenses such as audit fees, legal fees, repair and maintenance expenses incurred with respect to the Group's offices and medical equipment, printing expenses and bank charges.

Other expenses, net, increased by 8.2% from approximately HK\$27.0 million for 1HFY2021 to HK\$29.2 million for 1HFY2022, primarily due to increase of utilities, operation and other administrative expenses.

Summary of operational data for 1HFY2022 with comparative figures for 1HFY2021

Revenue by operating segment from continuing operations

折舊及攤銷

折舊及攤銷包括使用權資產折舊以及其他非流動資產之折舊及攤銷。2022財政年度上半年的有關開支與2021財政年度上半年相比維持穩定。

其他開支淨額

其他開支淨額主要包括減值虧損撥備以及日常開銷，例如水電、經營及其他行政開支（例如審核費用、法律費用、與本集團辦公室及醫療設備相關的維修及保養開支、印刷費及銀行收費）。

其他開支淨額由2021財政年度上半年的約27.0百萬港元增加8.2%至2022財政年度上半年的29.2百萬港元，主要由於公用事業、營運及其他行政開支增加。

2022財政年度上半年的經營數據與2021財政年度上半年比較數據概要

來自持續經營業務的按經營分部劃分收入

		Six months ended 31 December 截至12月31日止六個月		Increase/ (decrease)
		2021 2021年 HK\$'000 千港元 (Unaudited) (未經審核)	2020 2020年 HK\$'000 千港元 (Unaudited) (未經審核)	增加/ (減少)
Provision of corporate healthcare solution services in Hong Kong and Macau	於香港及澳門提供企業醫療保健解決方案服務	123,517	121,615	1.6%
Medical	醫療	112,435	109,815	2.4%
Dental	牙科	11,082	11,800	(6.1%)
Provision of clinical healthcare services in Hong Kong and Macau	於香港及澳門提供臨床醫療保健服務	211,988	160,122	32.4%
Medical	醫療	181,567	132,666	36.9%
Dental	牙科	30,421	27,456	10.8%
Mainland China Clinical Healthcare Business	中國內地臨床醫療保健業務	22,705	17,484	29.9%
TOTAL	合計	358,210	299,221	19.7%

Management Discussion and Analysis

管理層討論及分析

Number of visits by operating segment from continuing operation

來自持續經營業務的按經營分部劃分就診次數

		Six months ended 31 December		Increase/
		截至12月31日止六個月		(decrease)
		2021	2020	增加/
		2021年	2020年	(減少)
Provision of corporate healthcare solution services in Hong Kong and Macau	於香港及澳門提供企業醫療保健解決方案服務	490,020	408,427	20.0%
Medical	醫療	476,576	395,260	20.6%
Dental	牙科	13,444	13,167	2.1%
Provision of clinical healthcare services in Hong Kong and Macau	於香港及澳門提供臨床醫療保健服務	137,492	104,062	32.1%
Medical	醫療	119,286	89,647	33.1%
Dental	牙科	18,206	14,415	26.3%
Mainland China Clinical Healthcare Business	中國內地臨床醫療保健業務	17,478	15,480	12.9%
TOTAL	合計	644,990	527,969	22.2%

KEY FINANCIAL POSITION ITEMS

Right-of-use assets

Under HKFRS 16, right-of-use assets are recognised at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. The recognised right-of-use assets are depreciated on a straight-line basis over the shorter of the estimated useful life and the lease term.

As at 31 December 2021, the Group's right-of-use assets amounted to HK\$87.8 million (30 June 2021: HK\$73.7 million).

主要財務狀況項目

使用權資產

根據香港財務報告準則第16號，使用權資產於租賃開始日期確認。使用權資產按成本減去任何累計折舊和任何減值虧損後的金額計量，並就租賃負債的任何重新計量進行調整。使用權資產的成本包括已確認的租賃負債金額、已產生的初始直接成本以及在開始日期或之前已作出的租賃付款減已收到的任何租賃優惠。已確認的使用權資產以直線法按估計可使用年期和租期之較短者計提折舊。

於2021年12月31日，本集團的使用權資產為87.8百萬港元（2021年6月30日：73.7百萬港元）。

Management Discussion and Analysis

管理層討論及分析

Financial Assets at Amortised Cost

Financial assets at amortised cost primarily represent the marketable corporate bonds issued by listed corporations with fixed interest rates from 4.25% to 8.50% per annum. The marketable debt securities which will mature within one year and more than one year are classified as current assets and non-current assets, respectively. The Group receives related interest payments semi-annually and annually.

As at 31 December 2021 and 30 June 2021, the Group's financial assets at amortised cost amounted to HK\$33.0 million (of which HK\$26.6 million is classified as current assets and HK\$6.4 million is classified as non-current assets) and HK\$33.1 million (of which HK\$14.1 million is classified as current assets and HK\$19.0 million is classified as non-current assets), respectively.

Lease liabilities

Under HKFRS 16, lease liabilities are recognised at the commencement date of the lease at the present value of lease payments to be made over the lease term. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made.

As at 31 December 2021 and 30 June 2021, the carrying amount of lease liabilities amounted to HK\$91.1 million (of which HK\$44.4 million is classified as current liabilities and HK\$46.7 million is classified as non-current liabilities) and HK\$78.0 million (of which HK\$38.7 million is classified as current liabilities and HK\$39.3 million is classified as non-current liabilities).

LIQUIDITY AND FINANCIAL RESOURCES

The Group has historically funded its operations primarily by cash generated from operating activities. Upon the listing of the shares of the Company on the Hong Kong Stock Exchange, the Group intended to satisfy its liquidity requirements using a combination of cash generated from operating activities and net proceeds from the Global Offering. The Group may also seek to borrow to satisfy liquidity requirements. As of 31 December 2021, the Group had a cash and cash equivalents of HK\$259.4 million.

As of the date of this report, the Group did not have any bank borrowings or outstanding bank loans and did not enter into any bank loan facilities.

按攤銷成本計量的金融資產

按攤銷成本計量的金融資產主要指上市公司發行的適銷公司債券，按固定年利率4.25%至8.50%計息。於一年內及一年後到期的適銷債務證券分別分類為流動資產及非流動資產。本集團每半年及每年收取相關利息付款。

於2021年12月31日及2021年6月30日，本集團按攤銷成本計量的金融資產分別為33.0百萬港元（其中26.6百萬港元分類為流動資產而6.4百萬港元分類為非流動資產）及33.1百萬港元（其中14.1百萬港元分類為流動資產而19.0百萬港元分類為非流動資產）。

租賃負債

根據香港財務報告準則第16號，租賃負債在租賃開始日期以在租賃期內將作出的租賃付款的現值確認。在開始日期之後，租賃負債的金額予以上調以反映利息的增加，並就已作出的租賃付款而減少。

於2021年12月31日及2021年6月30日，租賃負債的賬面值分別為91.1百萬港元（其中44.4百萬港元分類為流動負債而46.7百萬港元分類為非流動負債）及78.0百萬港元（其中38.7百萬港元分類為流動負債而39.3百萬港元分類為非流動負債）。

流動資金及財務資源

本集團過往主要透過經營活動所得現金支持其業務經營。本公司股份於香港聯交所上市後，本集團擬動用經營活動所得現金及全球發售所得款項淨額來滿足其流動資金需求。本集團亦可能尋求借款來滿足流動資金需求。截至2021年12月31日，本集團持有的現金及現金等價物為259.4百萬港元。

截至本報告日期，本集團並無任何銀行借款或未償還銀行貸款，亦無訂立任何銀行貸款融資。

Management Discussion and Analysis

管理層討論及分析

CAPITAL STRUCTURE

There has been no significant change in the capital structure of the Company during the period ended 31 December 2021. The capital of the Company comprises ordinary shares and other reserves.

MATERIAL ACQUISITION OR DISPOSAL OF SUBSIDIARIES

On 31 December 2021, 55% shareholding of UMP Healthcare China Limited (“UMP Healthcare China”), an indirect non-wholly owned subsidiary of the Company, was disposed of at a consideration of HK\$22 million. Subsequent to the transaction, the Group’s shareholding in UMP Healthcare China decreased from 80% to 25% and the Group ceased control over UMP Healthcare China. As a result, UMP Healthcare China and its subsidiaries have become the associates of the Group. A resulting gain on disposal of HK\$15.4 million was recognised in profit and loss during the year.

Save as disclosed in this report, there was no material acquisition or disposal of subsidiaries undertaken by the Group during 1HFY2022.

CAPITAL EXPENDITURE

The capital expenditure during the period was primarily related to decoration and the acquisitions of plant and equipment for the Group’s medical centres. For 1HFY2022, the Group incurred capital expenditure in an aggregate amount of approximately HK\$28.0 million (1HFY2021: HK\$15.0 million).

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

The Group continues to strengthen its current business and explore growth opportunities. The Group did not have any specific future plan for material investments or capital assets as of 31 December 2021.

INDEBTEDNESS

Contingent Liabilities

As at 31 December 2021, the Group did not have any material off-balance sheet arrangements.

Capital Commitment

The Group has no material outstanding capital commitment as at 31 December 2021.

資本結構

截至2021年12月31日止期間，本公司的資本結構並無重大變動。本公司的資本包括普通股及其他儲備。

重大收購或出售附屬公司

於2021年12月31日，本公司間接非全資附屬公司聯合醫務中國有限公司（「聯合醫務中國」）的55%股權以22百萬港元的代價出售。交易完成後，本集團在聯合醫務中國的持股比例從80%降至25%而本集團不再控制聯合醫務中國。因此，聯合醫務中國及其附屬公司已成為本集團的聯營公司。出售產生的15.4百萬港元收益已於本期間的損益確認。

除本報告披露者外，本集團於2022財政年度上半年並無重大收購或出售附屬公司。

資本開支

期內資本開支主要有關裝修及為本集團醫務中心購置機器及設備。於2022財政年度上半年，本集團產生資本開支合共約28.0百萬港元（2021財政年度上半年：15.0百萬港元）。

重大投資或資本資產的未來計劃

本集團繼續加強現有業務及探求不同增長機遇。本集團於2021年12月31日並無任何重大投資或資本資產的具體未來計劃。

債務

或然負債

於2021年12月31日，本集團並無任何重大資產負債表外安排。

資本承擔

本集團於2021年12月31日並無重大未履行資本承擔。

Management Discussion and Analysis

管理層討論及分析

PLEDGE OF ASSETS

As at 31 December 2021, the Group has pledged certain deposits with an aggregate carrying amount of HK\$2.4 million (30 June 2021: HK\$1.9 million) in connection with a surety bond issued by a bank in favour of an independent third party for potential damages of dental equipment and potential disruption of Medical Services, and a bank guarantee issued by a bank in favour of a landlord for leasing of a medical centre of the Group.

EMPLOYEE AND REMUNERATION POLICY

As at 31 December 2021, the Group had a total of 476 (30 June 2021: 519) full-time employees. For 1HFY2022, the staff cost (including Directors' remuneration in the form of salaries and other benefits) was approximately HK\$83.9 million (1HFY2021: HK\$52.0 million).

The Group ensures that the pay levels of its employees are competitive and employees are rewarded on a performance related basis, together with reference to the profitability of the Group, prevailing remuneration benchmarks in the industry, and market conditions within the general framework of the Group's remuneration system.

In addition, the Company also adopted the Pre-IPO Share Option Scheme and the Post-IPO Share Option Scheme, where eligible employees and consultants are entitled to subscribe for the Shares for their contribution to the Group. As at 31 December 2021, 27,008,000 options remained outstanding under the Pre-IPO Share Option Scheme and none of the share options under the Pre-IPO Share Option Scheme have been exercised during 1HFY2022. As at 31 December 2021, 36,286,000 options were granted under the Post-IPO Share Option Scheme and none of the share options under the Post-IPO Share Option Scheme have been exercised during 1HFY2022.

The Company has also adopted the Share Award Scheme to provide an incentive and reward to selected participants for their contribution to the Group. No Shares have been purchased or granted under the Share Award Scheme during 1HFY2022.

資產抵押

於2021年12月31日，本集團抵押賬面值合共2.4百萬港元（2021年6月30日：1.9百萬港元）的若干存款，乃有關由一間銀行向一名獨立第三方就潛在牙科設備損壞及醫療服務的潛在干擾發出的履約保證以及由一間銀行就本集團租賃一間醫務中心向業主作出的銀行擔保。

僱員及薪酬政策

於2021年12月31日，本集團共有476名（2021年6月30日：519名）全職僱員。於2022財政年度上半年，員工成本（包括以薪金及其他福利形式的董事薪酬）約為83.9百萬港元（2021財政年度上半年：52.0百萬港元）。

本集團確保其僱員的薪金水平具競爭力，僱員按工作表現基準獲得獎勵，且經參考本集團盈利能力、行業內現行的薪酬基準以及本集團薪酬體系整體框架內的市場狀況。

此外，本公司亦採納首次公開發售前購股權計劃及首次公開發售後購股權計劃，而合資格僱員及顧問因彼等對本集團作出貢獻而有權認購股份。於2021年12月31日，27,008,000份購股權尚未根據首次公開發售前購股權計劃行使，並無購股權已於2022財政年度上半年根據首次公開發售前購股權計劃獲行使。於2021年12月31日，根據首次公開發售後購股權計劃授出的36,286,000份購股權尚未獲行使，並無購股權已於2022財政年度上半年根據首次公開發售後購股權計劃獲行使。

本公司亦採納股份獎勵計劃，以就選定參與者對本集團作出貢獻而向彼等提供獎勵及回報。於2022財政年度上半年，並無根據股份獎勵計劃購入或授出股份。

Management Discussion and Analysis 管理層討論及分析

The remuneration packages of the Directors are reviewed by the Remuneration Committee and approved by the Board, according to the relevant Director's experience, responsibility, workload and the time devoted to the Group, the Company's operating results and comparable market statistics.

INTERIM DIVIDEND

The Board has declared an interim dividend of HK1.50 cent per ordinary share for the six months ended 31 December 2021 (FY2021 interim dividend: HK1.00 cent). The interim dividend will be payable to the shareholders of the Company whose names appear on the register of members of the Company on Wednesday, 16 March 2022. It is expected that the interim dividend will be paid on or about Friday, 8 April 2022.

董事薪酬方案由薪酬委員會審閱並由董事會批准，乃根據相關董事的經驗、職責、工作量及於本集團投放的時間、本公司的經營業績及可資比較市場數據決定。

中期股息

董事會已宣派截至2021年12月31日止六個月的中期股息每股普通股1.50港仙(2021財政年度中期股息：1.00港仙)。中期股息將派付予於2022年3月16日(星期三)名列本公司股東名冊的本公司股東。預期中期股息將於2022年4月8日(星期五)或前後派付。

Corporate Governance Highlights

企業管治摘要

COMPLIANCE WITH THE CORPORATE GOVERNANCE PRACTICES

The Company is committed to maintaining high standards of corporate governance and transparency. The Company confirms that it has complied with the code provisions of the Corporate Governance Code contained in Appendix 14 to the Listing Rules during the six months ended 31 December 2021, save for the deviation from code provision A.2.1 as mentioned below.

According to code provision A.2.1 of the Corporate Governance Code, the roles of the chairman and chief executive should be separate and should not be performed by the same individual. Dr. Sun Yiu Kwong, the Chairman of the Board, is also the Chief Executive Officer. The Board believes that vesting the roles of both chairman and chief executive in an experienced and qualified person such as Dr. Sun Yiu Kwong provides the Company with strong and consistent leadership while allowing effective and efficient planning and implementation of business decisions and strategies. The Board considers that this structure will not impair the balance of power and authority between the Board and the management of the Group.

The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

THE BOARD

As of the date of this report, the Board comprised ten Directors, including six executive Directors, namely Dr. Sun Yiu Kwong as Chairman and Chief Executive Officer, Ms. Kwok Cheuk Kwan, Jacquen as Managing Director, Mr. Tsang On Yip, Patrick, Dr. Sun Man Kin, Michael, Mr. Lee Kar Chung, Felix and Dr. Lee Pak Cheung, Patrick; and four independent non-executive Directors, namely Mr. Lee Luen Wai, John *BBS JP*, Dr. Li Kwok Tung, Donald *SBS JP*, Mr. Yeung Wing Sun, Mike and Mr. Chau, Chit Jeremy.

遵守企業管治常規

本公司致力維持高水平的企業管治及透明度。本公司確認，除下文所述對於企業管治守則第A.2.1條之要求的偏離外，其於截至2021年12月31日止六個月已遵守上市規則附錄十四所載之企業管治守則的守則條文。

根據企業管治守則條文第A.2.1條，主席與行政總裁應有區分，並不應由一人同時兼任。孫耀江醫生為董事會主席亦為行政總裁。董事會認為，由孫耀江醫生這樣經驗豐富的合資格人士擔任主席兼行政總裁可為本公司提供強而有力和穩定的領導，同時確保對業務決策及策略作出有效及高效的規劃和實施。董事會認為，此結構不會影響本集團董事會與管理層之間的權力及授權平衡。

董事會將不時審閱企業管治架構及常規，並於其認為適當時作出必要安排。

董事會

於本報告日期，董事會由十位董事組成，包括六位執行董事，分別為孫耀江醫生（作為主席兼行政總裁）、郭卓君女士（作為董事總經理）、曾安業先生、孫文堅醫生、李家聰先生及李柏祥醫生；及四位獨立非執行董事，分別為李聯偉先生（*銅紫荊星章，太平紳士*）、李國棟醫生（*銀紫荊星章，太平紳士*）、楊榮燦先生及周哲先生。

Corporate Governance Highlights

企業管治摘要

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct for dealing in securities of the Company by the Directors.

Having made specific enquiry with all Directors, the Company confirmed that the Directors have complied with the Model Code during the six months ended 31 December 2021.

Relevant employees who are likely to be in possession of inside information of the Group are also subject to compliance with the Code of Conduct for Securities Transactions by Employees on terms that are no less exacting than those set out in the Model Code. To the best knowledge of the Company, there was no incident of non-compliance of the Code of Conduct for Securities Transactions by Employees during the six months ended 31 December 2021.

REVIEW OF INTERIM RESULTS

The Audit Committee, which comprises three independent non-executive Directors, namely Mr. Lee Luen Wai, John *BBS JP* (Chairman), Dr. Li Kwok Tung, Donald *SBS JP* and Mr. Yeung Wing Sun, Mike, has reviewed, together with the management of the Company, the unaudited interim results of the Group for the six months ended 31 December 2021 and considered that they were prepared in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that the Company has made appropriate disclosure thereof.

進行證券交易的標準守則

本公司已採納標準守則作為董事買賣本公司證券的行為守則。

經對全體董事作出具體查詢後，本公司確認董事於截至2021年12月31日止六個月內均遵守標準守則。

可能掌握本集團內幕消息的相關僱員亦須遵守僱員進行證券交易的操守準則，其條款不遜於標準守則所訂標準。就本公司所知，截至2021年12月31日止六個月並無出現違反僱員進行證券交易的操守準則的情況。

審閱中期業績

審核委員會由三名獨立非執行董事組成，即李聯偉先生(銅紫荊星章，太平紳士)(主席)、李國棟醫生(銀紫荊星章，太平紳士)及楊榮樂先生，彼等已與本公司管理層審閱本集團截至2021年12月31日止六個月的未經審核中期業績，並認為該等中期業績已根據有關會計準則、上市規則及適用法律規定編製，且本公司已作出適當披露。

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 31 December 2021, the interests and short positions of the Directors and Chief Executive of the Company in the shares, underlying shares and/or debentures (as the case may be) of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO) or which were required to be entered into the register required to be kept by the Company under section 352 of the SFO or which were otherwise required to be notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code were set out below:

(I) The Company

Name of Director 董事姓名	Long/short position 好倉/淡倉	Capacity 身份	Number of Shares/ underlying shares 股份/相關股份數目	Notes 附註	Approximate percentage of shareholding 概約持股比例 (%)
Dr. Sun Yiu Kwong 孫耀江醫生	Long position 好倉	Beneficial owner 實益擁有人	22,926,000		
	Long position 好倉	Interest held by his controlled corporations 權益由其控制法團持有	253,994,049	1	
	Long position 好倉	Beneficial owner 實益擁有人	700,000	3	
	Long position 好倉	Beneficial owner 實益擁有人	2,300,000	4	
	Long position 好倉	Beneficial owner 實益擁有人	1,000,000	5	
			280,920,049		36.23
Ms. Kwok Cheuk Kwan, Jacquen 郭卓君女士	Long position 好倉	Beneficial owner 實益擁有人	17,948,657		
	Long position 好倉	Beneficial owner 實益擁有人	11,380,000	2	
	Long position 好倉	Beneficial owner 實益擁有人	500,000	3	
	Long position 好倉	Beneficial owner 實益擁有人	1,500,000	4	
	Long position 好倉	Beneficial owner 實益擁有人	1,000,000	5	
			32,328,657		4.17

董事及最高行政人員於股份、相關股份及債權證的權益及淡倉

於2021年12月31日，董事及本公司最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）之股份、相關股份及／或債權證（視乎情況而定）中，擁有根據證券及期貨條例第XV部第7及第8分部而須知會本公司及香港聯交所之權益及淡倉（包括彼等根據該等證券及期貨條例條文而被視作或當作擁有之權益及淡倉），或根據證券及期貨條例第352條須記錄於本公司存置之登記名冊內之權益及淡倉，或根據標準守則而須知會本公司及香港聯交所之權益及淡倉如下：

(I) 本公司

Other Information 其他資料

Name of Director 董事姓名	Long/short position 好倉/淡倉	Capacity 身份	Number of Shares/ underlying shares 股份/相關股份數目	Notes 附註	Approximate percentage of shareholding 概約持股比例 (%)
Mr. Tsang On Yip, Patrick 曾安業先生	Long position 好倉	Beneficial owner 實益擁有人	4,486,000		
	Long position 好倉	Beneficial owner 實益擁有人	600,000	2	
	Long position 好倉	Beneficial owner 實益擁有人	400,000	3	
	Long position 好倉	Beneficial owner 實益擁有人	1,500,000	4	
	Long position 好倉	Beneficial owner 實益擁有人	1,000,000	5	
			7,986,000		1.03
Dr. Sun Man Kin, Michael 孫文堅醫生	Long position 好倉	Beneficial owner 實益擁有人	17,328,000		
	Long position 好倉	Beneficial owner 實益擁有人	400,000	3	
	Long position 好倉	Beneficial owner 實益擁有人	1,500,000	4	
	Long position 好倉	Beneficial owner 實益擁有人	1,000,000	5	
			20,228,000		2.61
Mr. Lee Kar Chung, Felix 李家聰先生	Long position 好倉	Beneficial owner 實益擁有人	11,388,000		
	Long position 好倉	Beneficial owner 實益擁有人	10,242,000	2	
	Long position 好倉	Beneficial owner 實益擁有人	500,000	3	
	Long position 好倉	Beneficial owner 實益擁有人	1,500,000	4	
	Long position 好倉	Beneficial owner 實益擁有人	1,000,000	5	
			24,630,000		3.18
Dr. Lee Pak Cheung, Patrick 李柏祥醫生	Long position 好倉	Beneficial owner 實益擁有人	21,115,293		
	Long position 好倉	Beneficial owner 實益擁有人	400,000	3	
	Long position 好倉	Beneficial owner 實益擁有人	1,500,000	4	
	Long position 好倉	Beneficial owner 實益擁有人	1,000,000	5	
			24,015,293		3.10

Other Information 其他資料

Name of Director 董事姓名	Long/short position 好倉/淡倉	Capacity 身份	Number of Shares/ underlying shares 股份/相關股份數目	Notes 附註	Approximate percentage of shareholding 概約持股比例 (%)
Mr. Lee Luen Wai, John <i>BBS JP</i> 李聯偉先生(銅紫荊星章, 太平紳士)	Long position 好倉	Beneficial owner 實益擁有人	2,002,848		
	Long position 好倉	Beneficial owner 實益擁有人	300,000	4	
			2,302,848		0.30
Dr. Li Kwok Tung, Donald <i>SBS JP</i> 李國棟醫生(銀紫荊星章, 太平紳士)	Long position 好倉	Beneficial owner 實益擁有人	328,000		
	Long position 好倉	Beneficial owner 實益擁有人	300,000	4	
			628,000		0.08
Mr. Yeung Wing Sun, Mike 楊榮樂先生	Long position 好倉	Beneficial owner 實益擁有人	500,000		
	Long position 好倉	Beneficial owner 實益擁有人	200,000	4	
			700,000		0.09

Notes:

- (1) Dr. Sun Yiu Kwong was deemed to be interested in the 207,988,049 Shares held by East Majestic Group Limited, being his controlled corporation, and was also deemed to be interested in 46,006,000 Shares held by EM Team Limited, also being his controlled corporation.
- (2) These Shares represented the underlying Shares under the options granted by the Company on 18 August 2015 pursuant to the Pre-IPO Share Option Scheme.
- (3) These Shares represented the share award granted by the Company on 17 July 2018 pursuant to the Share Award Scheme.
- (4) These Shares represented the underlying Shares under the options granted by the Company on 6 November 2018 pursuant to the Post-IPO Share Option Scheme.
- (5) These Shares represented the underlying Shares under the options granted by the Company on 26 May 2021 pursuant to the Post-IPO Share Option Scheme.

附註:

- (1) 孫耀江醫生被視為於彼控制之法團 East Majestic Group Limited 持有的 207,988,049 股股份中擁有權益。孫耀江醫生亦被視為於同樣為彼控制之法團 EM Team Limited 持有的 46,006,000 股股份中擁有權益。
- (2) 該等股份指本公司於 2015 年 8 月 18 日根據首次公開發售前購股權計劃授出的購股權項下的相關股份。
- (3) 該等股份指本公司於 2018 年 7 月 17 日根據股份獎勵計劃授出的股份獎勵項下的相關股份。
- (4) 該等股份指本公司於 2018 年 11 月 6 日根據首次公開發售後購股權計劃授出的購股權項下的相關股份。
- (5) 該等股份指本公司於 2021 年 5 月 26 日根據首次公開發售後購股權計劃授出的購股權項下的相關股份。

Other Information 其他資料

(II) Associated Corporations (within the meaning of the SFO) Procure Medical Imaging & Laboratory Centre Limited⁽¹⁾

Name of Director 董事姓名	Long/short position 好倉／淡倉	Capacity 身份	Number of shares 股份數目	Approximate percentage of shareholding 概約持股比例 (%)
Dr. Sun Man Kin, Michael 孫文堅醫生	Long position 好倉	Beneficial owner 實益擁有人	625	6.25

Causeway Bay MRI Centre Limited⁽²⁾

Name of Director 董事姓名	Long/short position 好倉／淡倉	Capacity 身份	Number of shares 股份數目	Approximate percentage of shareholding 概約持股比例 (%)
Dr. Sun Man Kin, Michael 孫文堅醫生	Long position 好倉	Beneficial owner 實益擁有人	95	6.33

Notes:

- (1) UMP Medical Centre Limited, a wholly-owned subsidiary of the Company, holds 62.5% of the entire issued share capital of Procure Medical Imaging & Laboratory Centre Limited.
- (2) UMP Medical Centre Limited, a wholly-owned subsidiary of the Company, holds 20% of the entire issued share capital of Causeway Bay MRI Centre Limited.

Save as disclosed above, as at 31 December 2021, none of the Directors or Chief Executive of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or as otherwise notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code.

UPDATE ON DIRECTORS' INFORMATION

The following is updated information of the Directors required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules:

Mr. Chau, Chit Jeremy was appointed as an independent non-executive Director with effect from 26 November 2021.

Further details of the appointment can be found in the announcement of the Company dated 26 November 2021.

(II) 相聯法團(定義見證券及期貨條例) 普康醫學影像及化驗中心有限公司⁽¹⁾

銅鑼灣磁力共振中心有限公司⁽²⁾

附註：

- (1) 本公司的全資附屬公司聯合醫務中心有限公司持有普康醫學影像及化驗中心有限公司的全部已發行股本的62.5%。
- (2) 本公司的全資附屬公司聯合醫務中心有限公司持有銅鑼灣磁力共振中心有限公司的全部已發行股本的20%。

除上文所披露外，於2021年12月31日，董事或本公司最高行政人員於本公司及其相聯法團(定義見證券及期貨條例第XV部)之股份、相關股份及債權證中，概無擁有根據證券及期貨條例第XV部第7及第8分部而須知會本公司及香港聯交所之權益或淡倉(包括彼等根據該等證券及期貨條例條文而被視作或當作擁有之權益或淡倉)，或須記錄於根據證券及期貨條例第352條存置之登記名冊內之權益或淡倉，或根據標準守則而須知會本公司及香港聯交所之權益或淡倉。

董事資料更新

根據上市規則第13.51B(1)條須予披露之董事資料更新如下：

周哲先生於2021年11月26日起獲委任為獨立非執行董事。

有關此項委任之進一步詳情請參閱日期為2021年11月26日的本公司公告。

SHARE OPTION SCHEMES

The Company has adopted two share option schemes, namely the Pre-IPO Share Option Scheme and the Post-IPO Share Option Scheme.

(A) Pre-IPO Share Option Scheme

The Company adopted the Pre-IPO Share Option Scheme on 18 August 2015 under which the maximum number of Shares to be issued upon full exercise of all outstanding share options is 27,008,000, being approximately 3.48% of the issued share capital of the Company as at 31 December 2021.

Details of the options granted and outstanding under the Pre-IPO Share Option Scheme are set out as follows:

Grantee	Position	Date of grant (dd/mm/yy) (日/月/年)	Exercise price per Share (HK\$) (港元)	Exercise period (dd/mm/yy) (日/月/年)	Number of Shares issuable under the share options 購股權項下可予發行股份數目				
					As at 1 July 2021 於2021年 7月1日	Granted during the period 期內已授出	Exercised during the period 期內已行使	Cancelled/ Lapsed during the period 期內已 註銷/失效	As at 31 December 2021 於2021年 12月31日
Directors 董事									
Ms. Kwok Cheuk Kwan, Jacquen 郭卓君女士	Managing Director and Executive Director 董事總經理兼執行董事	18/08/2015	1.2228	18/08/2016–26/11/2022 18/08/2017–26/11/2022	1,138,000 10,242,000	-	-	-	1,138,000 10,242,000
Mr. Tsang On Yip, Patrick 曾安業先生	Executive Director 執行董事	18/08/2015	1.2228	18/08/2016–26/11/2022 18/08/2017–26/11/2022	60,000 540,000	-	-	-	60,000 540,000
Mr. Lee Kar Chung, Felix 李家聰先生	Executive Director 執行董事	18/08/2015	1.2228	18/08/2017–26/11/2022	10,242,000	-	-	-	10,242,000
				Sub-total: 小計:	22,222,000	-	-	-	22,222,000
Employees 僱員									
In aggregate 合共	-	18/08/2015	1.2228	18/08/2017–26/11/2022	3,186,000	-	-	-	3,186,000
				Sub-total: 小計:	3,186,000	-	-	-	3,186,000
Other eligible grantees 其他合資格承授人									
In aggregate 合共	-	18/08/2015	1.2228	18/08/2016–26/11/2022 18/08/2017–26/11/2022	160,000 1,440,000	-	-	-	160,000 1,440,000
				Sub-total: 小計:	1,600,000	-	-	-	1,600,000
				Total: 總計:	27,008,000	-	-	-	27,008,000

As at 31 December 2021, 27,008,000 options remained outstanding under the Pre-IPO Share Option Scheme.

購股權計劃

本公司已採納兩項購股權計劃，即首次公開發售前購股權計劃及首次公開發售後購股權計劃。

(A) 首次公開發售前購股權計劃

本公司已於2015年8月18日採納首次公開發售前購股權計劃，於所有尚未行使購股權獲悉數行使後，其項下可發行之股份數目上限為27,008,000股，即本公司於2021年12月31日已發行股本約3.48%。

於首次公開發售前購股權計劃項下授出及未行使的購股權詳情載列如下：

Grantee	Position	Date of grant (dd/mm/yy) (日/月/年)	Exercise price per Share (HK\$) (港元)	Exercise period (dd/mm/yy) (日/月/年)	Number of Shares issuable under the share options 購股權項下可予發行股份數目				
					As at 1 July 2021 於2021年 7月1日	Granted during the period 期內已授出	Exercised during the period 期內已行使	Cancelled/ Lapsed during the period 期內已 註銷/失效	As at 31 December 2021 於2021年 12月31日
Directors 董事									
Ms. Kwok Cheuk Kwan, Jacquen 郭卓君女士	Managing Director and Executive Director 董事總經理兼執行董事	18/08/2015	1.2228	18/08/2016–26/11/2022 18/08/2017–26/11/2022	1,138,000 10,242,000	-	-	-	1,138,000 10,242,000
Mr. Tsang On Yip, Patrick 曾安業先生	Executive Director 執行董事	18/08/2015	1.2228	18/08/2016–26/11/2022 18/08/2017–26/11/2022	60,000 540,000	-	-	-	60,000 540,000
Mr. Lee Kar Chung, Felix 李家聰先生	Executive Director 執行董事	18/08/2015	1.2228	18/08/2017–26/11/2022	10,242,000	-	-	-	10,242,000
				Sub-total: 小計:	22,222,000	-	-	-	22,222,000
Employees 僱員									
In aggregate 合共	-	18/08/2015	1.2228	18/08/2017–26/11/2022	3,186,000	-	-	-	3,186,000
				Sub-total: 小計:	3,186,000	-	-	-	3,186,000
Other eligible grantees 其他合資格承授人									
In aggregate 合共	-	18/08/2015	1.2228	18/08/2016–26/11/2022 18/08/2017–26/11/2022	160,000 1,440,000	-	-	-	160,000 1,440,000
				Sub-total: 小計:	1,600,000	-	-	-	1,600,000
				Total: 總計:	27,008,000	-	-	-	27,008,000

於2021年12月31日，首次公開發售前購股權計劃項下有27,008,000份購股權尚未行使。

Other Information 其他資料

(B) Post-IPO Share Option Scheme

The Company adopted the Post-IPO Share Option Scheme on 2 November 2015 under which the maximum number of Share to be issued upon full exercise of all outstanding share option is 10,306,000 Shares, being approximately 1.33% of the issued share capital of the Company as at 31 December 2021.

Details of the options granted and outstanding under the Post-IPO Share Option Scheme are set out as follows:

(B) 首次公開發售後購股權計劃

本公司於2015年11月2日已採納首次公開發售後購股權計劃，於所有尚未行使購股權獲悉數行使其項下可發行之股份數目上限為10,306,000股股份，即本公司於2021年12月31日已發行股本之約1.33%。

首次公開發售後購股權計劃項下已授出及尚未行使之購股權詳情載列如下：

Grantee 承授人	Position 職位	Date of grant 授出日期 (dd/mm/yyyy) (日/月/年)	Exercise price per Share 每股行使價 (HK\$) (港元)	Exercise period 行使期 (dd/mm/yyyy) (日/月/年)	As at 1 July 2021 於2021年 7月1日	Granted during the period 期內已授出	Exercised during the period 期內已行使	Cancelled/ Lapsed during the period 期內已 註銷/失效	As at 31 December 2021 於2021年 12月31日
Directors									
董事									
Dr. Sun Yiu Kwong 孫耀江醫生	Chairman, Chief Executive Officer and Executive Director	06/11/2018	2.06	30/06/2019 - 05/11/2023	2,300,000	-	-	-	2,300,000
		26/05/2021	0.772	26/05/2022 - 25/05/2029	400,000	-	-	-	400,000
	主席、行政總裁兼 執行董事	26/05/2021	0.772	26/05/2023 - 25/05/2029	300,000	-	-	-	300,000
		26/05/2021	0.772	26/05/2024 - 25/05/2029	300,000	-	-	-	300,000
Ms. Kwok Cheuk Kwan, Jacquen 郭卓君女士	Managing Director and Executive Director	06/11/2018	2.06	30/06/2019 - 05/11/2023	1,500,000	-	-	-	1,500,000
		26/05/2021	0.772	26/05/2022 - 25/05/2029	400,000	-	-	-	400,000
	董事總經理兼執行董事	26/05/2021	0.772	26/05/2023 - 25/05/2029	300,000	-	-	-	300,000
		26/05/2021	0.772	26/05/2024 - 25/05/2029	300,000	-	-	-	300,000
Mr. Tsang On Yip, Patrick 曾安業先生	Executive Director	06/11/2018	2.06	30/06/2019 - 05/11/2023	1,500,000	-	-	-	1,500,000
		26/05/2021	0.772	26/05/2022 - 25/05/2029	400,000	-	-	-	400,000
	執行董事	26/05/2021	0.772	26/05/2023 - 25/05/2029	300,000	-	-	-	300,000
		26/05/2021	0.772	26/05/2024 - 25/05/2029	300,000	-	-	-	300,000
Dr. Sun Man Kin, Michael 孫文堅醫生	Executive Director	06/11/2018	2.06	30/06/2019 - 05/11/2023	1,500,000	-	-	-	1,500,000
		26/05/2021	0.772	26/05/2022 - 25/05/2029	400,000	-	-	-	400,000
	執行董事	26/05/2021	0.772	26/05/2023 - 25/05/2029	300,000	-	-	-	300,000
		26/05/2021	0.772	26/05/2024 - 25/05/2029	300,000	-	-	-	300,000

Other Information 其他資料

Grantee 承授人	Position 職位	Date of grant 授出日期 (dd/mm/yyyy) (日/月/年)	Exercise price per Share 每股行使價 (HK\$) (港元)	Exercise period 行使期 (dd/mm/yyyy) (日/月/年)	As at 1 July 2021 於2021年 7月1日	Granted during the period 期內已授出	Exercised during the period 期內已行使	Cancelled/ Lapsed during the period 期內已 註銷/失效	As at 31 December 2021 於2021年 12月31日
Mr. Lee Kar Chung, Felix 李家聰先生	Executive Director 執行董事	06/11/2018	2.06	30/06/2019 - 05/11/2023	1,500,000	-	-	-	1,500,000
		26/05/2021	0.772	26/05/2022 -25/05/2029	400,000	-	-	-	400,000
		26/05/2021	0.772	26/05/2023 -25/05/2029	300,000	-	-	-	300,000
		26/05/2021	0.772	26/05/2024 -25/05/2029	300,000	-	-	-	300,000
Dr. Lee Pak Cheung, Patrick 李柏祥醫生	Executive Director 執行董事	06/11/2018	2.06	30/06/2019 - 05/11/2023	1,500,000	-	-	-	1,500,000
		26/05/2021	0.772	26/05/2022 -25/05/2029	400,000	-	-	-	400,000
		26/05/2021	0.772	26/05/2023 -25/05/2029	300,000	-	-	-	300,000
		26/05/2021	0.772	26/05/2024 -25/05/2029	300,000	-	-	-	300,000
Mr. Lee Luen Wai, John BBS JP 李聯偉先生(銅紫荊星章·太平紳士)	Independent Non-executive Director 獨立非執行董事	06/11/2018	2.06	30/06/2019 - 05/11/2023	300,000	-	-	-	300,000
Dr. Li Kwok Tung, Donald SBS JP 李國棟醫生(銅紫荊星章·太平紳士)	Independent Non-executive Director 獨立非執行董事	06/11/2018	2.06	30/06/2019 - 05/11/2023	300,000	-	-	-	300,000
Mr. Yeung Wing Sun, Mike 楊榮樂先生	Independent Non-executive Director 獨立非執行董事	06/11/2018	2.06	30/06/2019 - 05/11/2023	200,000	-	-	-	200,000
				Sub-total 小計	16,600,000	-	-	-	16,600,000

Other Information 其他資料

Grantee 承授人	Position 職位	Date of grant 授出日期 (dd/mm/yyyy) (日/月/年)	Exercise price per Share 每股行使價 (HK\$) (港元)	Exercise period 行使期 (dd/mm/yyyy) (日/月/年)	As at 1 July 2021 於2021年 7月1日	Granted during the period 期內已授出	Exercised during the period 期內已行使	Cancelled/ Lapsed during the period 期內已 註銷/失效	As at 31 December 2021 於2021年 12月31日
Employees									
僱員									
In aggregate									
合計									
		06/11/2018	2.06	30/06/2019 - 05/11/2023	1,000,000	-	-	-	1,000,000
		05/05/2019	1.56	04/05/2020 - 03/05/2025	250,000	-	-	-	250,000
		05/05/2019	1.56	04/05/2021 - 03/05/2025	500,000	-	-	-	500,000
		05/05/2019	1.56	04/05/2022 - 03/05/2025	750,000	-	-	-	750,000
		26/05/2021	0.772	26/05/2022 -25/05/2029	5,874,400	-	-	-	5,874,400
		26/05/2021	0.772	26/05/2023 -25/05/2029	4,405,800	-	-	-	4,405,800
		26/05/2021	0.772	26/05/2024 -25/05/2029	4,405,800	-	-	-	4,405,800
				Sub-total 小計	17,186,000	-	-	-	17,186,000
Other eligible grantee(s)									
其他合資格承授人									
In aggregate									
合計									
		06/11/2018	2.06	30/06/2019 - 05/11/2023	1,000,000	-	-	-	1,000,000
		05/05/2019	1.56	04/05/2020 - 03/05/2025	250,000	-	-	-	250,000
		05/05/2019	1.56	04/05/2021 - 03/05/2025	500,000	-	-	-	500,000
		05/05/2019	1.56	04/05/2022 - 03/05/2025	750,000	-	-	-	750,000
				Sub-total 小計	2,500,000	-	-	-	2,500,000
				Total 總計	36,286,000	-	-	-	36,286,000

As at 31 December 2021, none of options granted under the Post-IPO Share Option Scheme during the six months ended 31 December 2021.

於2021年12月31日，概無根據首次公開發售後購股權計劃於截至2021年12月31日止六個月授出購股權。

SHARE AWARD SCHEME

The Company has adopted the Share Award Scheme on 30 June 2016 to recognise the contributions of and provide incentives for the key management personnel including Directors and senior management, employed experts and employees of the Group. Subject to any early termination as may be determined by the Board, pursuant to the trust deed, the Share Award Scheme shall be valid and effective for a term of 10 years commencing on the adoption date. The maximum number of Shares which may be awarded to a selected participant under the Share Award Scheme shall not exceed 1% of the issued share capital of the Company in each year. The Board shall not make any further award of the awarded Shares which will result in the nominal value of the Shares awarded by the Board under the Share Award Scheme exceeding 2% of the issued share capital of the Company from time to time.

Details of the share award granted and outstanding under the Share Award Scheme are set out as follows:

Name or category of participant 參與人姓名或類別	As at 1 July 2021 於2021年7月1日	Granted during the period 期內授出	Vested during the period 期內歸屬	Cancelled/lapsed during the period 期內註銷/失效	As at 31 December 2021 於2021年12月31日
Directors 董事	2,900,000	-	-	-	2,900,000 (Note 1) (附註1)
Other eligible grantees(s) 其他合資格承授人	350,000	-	-	-	350,000 (Note 1) (附註1)
	2,330,000	-	-	-	2,330,000 (Note 1) (附註1)
In aggregate 總計	5,580,000	-	-	-	5,580,000

Note:

- These awarded shares were granted on 17 July 2018 with the exercise price of HK\$1.5 per award shares.

No Shares have been purchased or granted under the Share Award Scheme during the period and none of shares have been vested during the period up to 31 December 2021.

股份獎勵計劃

本公司已於2016年6月30日採納股份獎勵計劃，嘉獎及獎勵主要管理人員（包括董事及高級管理層、本集團受僱專家及僱員）所作貢獻。受董事會可能釐定的任何提前終止所限，根據信託契據，股份獎勵計劃於採納日期起計十年期間有效及生效。根據股份獎勵計劃可授予選定參與者的股份數目上限不得超過本公司各年已發行股本的1%。董事會不得授出任何會導致董事會根據股份獎勵計劃授出超過本公司不時已發行股本2%之股份面值的進一步獎勵股份。

股份獎勵計劃項下已授出及尚未行使之股份獎勵詳情載列如下：

附註：

- 此等獎勵股份是於2018年7月17日授出，行使價為每股獎勵股份1.5港元。

期內並無根據股份獎勵計劃購買或授出股份，直至2021年12月31日止期間並無股份歸屬。

Other Information 其他資料

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 31 December 2021, so far as was known to the Directors of the Company, the following persons/entities (other than the Directors or Chief Executive of the Company) had, or were deemed to have, interests or short positions in the Shares or underlying shares of the Company which would fall to be disclosed to the Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO:

主要股東於本公司股份及相關股份的權益及淡倉

於2021年12月31日，據本公司董事所知，以下人士／實體（董事或本公司最高行政人員除外）於本公司之股份或相關股份中擁有或被視為擁有以下權益或淡倉而須根據證券及期貨條例第XV部第2及3分部條文須向本公司及香港聯交所披露，或記錄於本公司須根據證券及期貨條例第336條存置之登記名冊內：

Name of substantial shareholder	Long/short position	Capacity	Number of Shares/ underlying shares	Interests under equity derivatives	Notes	Approximate percentage of shareholding
主要股東姓名／名稱	好倉／淡倉	身份	股份／相關股份數目	股本衍生工具項下之權益	附註	概約持股比例 (%)
East Majestic Group Limited	Long position 好倉	Beneficial owner 實益擁有人	207,988,049	-	1	26.83
EM Team Limited	Long position 好倉	Beneficial owner 實益擁有人	46,006,000	-	1	5.93
Cheng Yu Tung Family (Holdings II) Limited	Long position 好倉	Interest held by its controlled corporations 權益由其控制法團持有	115,050,169	-	2	14.84
Cheng Yu Tung Family (Holdings) Limited	Long position 好倉	Interest held by its controlled corporations 權益由其控制法團持有	115,050,169	-	2	14.84
Chow Tai Fook Capital Limited	Long position 好倉	Interest held by its controlled corporation 權益由其控制法團持有	115,050,169	-	2	14.84
Chow Tai Fook (Holding) Limited 周大福(控股)有限公司	Long position 好倉	Interest held by its controlled corporations 權益由其控制法團持有	115,050,169	-	2	14.84
Chow Tai Fook Enterprises Limited 周大福企業有限公司	Long position 好倉	Interest held by its controlled corporation 權益由其控制法團持有	115,050,169	-	2	14.84
Healthcare Ventures	Long position 好倉	Beneficial owner 實益擁有人	115,050,169	-	2	14.84
China Resources Company Limited 中國華潤有限公司	Long position 好倉	Interest held by its controlled corporations 權益由其控制法團持有	91,803,000	-	3	11.84
CR Medical 華潤醫療	Long position 好倉	Interest held by its controlled corporations 權益由其控制法團持有	91,803,000	-	3	11.84

Notes:

1. Dr. Sun Yiu Kwong was deemed to be interested in the 207,988,049 Shares held by East Majestic Group Limited, being his controlled corporation, and was also deemed to be interested in the 46,006,000 Shares held by EM Team Limited, also being his controlled corporation. Dr. Sun's interests in Shares are disclosed in this interim report in the section headed "Directors' and Chief Executive interests and Short Positions in Shares, Underlying Shares and Debentures".
2. Healthcare Ventures was wholly owned by Chow Tai Fook Enterprises Limited ("CTFE"), which was wholly owned by Chow Tai Fook (Holding) Limited ("CTFH"). So far as the Company is aware, CTFH was held as to 81.03% by Chow Tai Fook Capital Limited ("CTFC"), which was in turn held as to 48.98% by Cheng Yu Tung Family (Holdings) Limited ("CYTF") and as to 46.65% by Cheng Yu Tung Family (Holdings II) Limited ("CYTFII"). By virtue of the SFO, CTFE, CTFH, CTFC, CYTF and CYTFII were deemed to be interested in the same parcel of Shares in which Healthcare Ventures was interested.
3. Pinyu Limited was the beneficial owner of the Shares. Pinyu Limited was wholly owned by Unison Champ Premium Limited, which was wholly owned by CR Medical. CR Medical was held as to 35.76% by CRH (Medical) Limited. CRH (Medical) Limited was wholly owned by China Resources Healthcare Group Limited, which was wholly owned by CRH (Healthcare) Limited. CRH (Healthcare) Limited was wholly owned by China Resources (Holdings) Company Limited, which was wholly owned by CRC Bluesky Limited. CRC Bluesky Limited was wholly owned by China Resources Inc., which was wholly owned by China Resources Company Limited. Commotra Company Limited held 0.82% of CR Medical Commotra Company Limited is wholly owned by China Resources (Holdings) Company Limited. By virtue of the SFO, Unison Champ Premium Limited, CR Medical, CRH (Medical) Limited, China Resources Healthcare Group Limited, CRH (Healthcare) Limited, China Resources Inc., China Resources (Holdings) Company Limited, CRC Bluesky Limited and China Resources Company Limited were deemed to be interested in the same parcel of Shares in which Pinyu Limited was interested.

Other than as disclosed above, as at 31 December 2021, the Directors have not been notified by any person (other than the Directors or Chief Executive of the Company) who had interests or short positions in the Shares or underlying shares of the Company as recorded in the register required to be kept pursuant to Section 336 of the SFO.

附註：

1. 孫耀江醫生被視為於彼控制之法團East Majestic Group Limited持有的207,988,049股股份中擁有權益。孫醫生亦被視為於同樣由彼控制之法團EM Team Limited持有的46,006,000股股份中擁有權益。孫醫生於股份之權益已於本中期報告「董事及最高行政人員於股份、相關股份及債權證的權益及淡倉」一節披露。
2. 醫療創業控股由周大福企業有限公司（「周大福企業」）全資擁有，而周大福企業由周大福（控股）有限公司（「CTFH」）全資擁有。就本公司所知，CTFH由Chow Tai Fook Capital Limited（「CTFC」）持有81.03%的股權，而CTFC分別由Cheng Yu Tung Family (Holdings) Limited（「CYTF」）及Cheng Yu Tung Family (Holdings II) Limited（「CYTFII」）持有48.98%及46.65%的股權。根據證券及期貨條例，周大福企業、CTFH、CTFC、CYTF及CYTFII被視為於醫療創業控股擁有權益的同一批股份中擁有權益。
3. 品裕有限公司為股份之實益擁有人。品裕有限公司由Unison Champ Premium Limited全資擁有，而Unison Champ Premium Limited由華潤醫療全資擁有。華潤醫療由華潤集團（醫療）有限公司擁有35.76%。華潤集團（醫療）有限公司由華潤健康集團有限公司全資擁有，而華潤健康集團有限公司由華潤集團（健康）有限公司全資擁有。華潤集團（健康）有限公司由華潤（集團）有限公司全資擁有，而華潤（集團）有限公司由CRC Bluesky Limited全資擁有。CRC Bluesky Limited由華潤股份有限公司全資擁有，而華潤股份有限公司由中國華潤有限公司全資擁有。合質有限公司持有CR Medical Commotra Company Limited的0.82%而CR Medical Commotra Company Limited由華潤（集團）有限公司全資擁有。根據證券及期貨條例，Unison Champ Premium Limited、華潤醫療、華潤集團（醫療）有限公司、華潤健康集團有限公司、華潤集團（健康）有限公司、華潤股份有限公司、華潤（集團）有限公司、CRC Bluesky Limited及中國華潤有限公司被視為於品裕有限公司擁有權益的同一批股份中擁有權益。

除上文披露外，於2021年12月31日，董事並無知悉任何人士（董事或本公司最高行政人員除外）於本公司股份或相關股份中擁有根據證券及期貨條例第336條須存置的登記名冊所記錄的權益或淡倉。

Other Information 其他資料

INTERIM DIVIDEND

The Board declared an interim dividend of HK1.50 cent (the corresponding period in 2020: HK1.00 cent) per Share for the six months ended 31 December 2021.

The interim dividend will be payable to the shareholders of the Company whose names appear on the register of members of the Company on Wednesday, 16 March 2022. It is expected that the interim dividend will be paid on or about Friday, 8 April 2022.

CLOSURE OF REGISTER OF MEMBERS

Book close dates : Monday, 14 March 2022 to
(both days inclusive) Wednesday, 16 March 2022

Latest time to lodge transfer : 4:30 p.m. on Friday,
with share registrar 11 March 2022

Address of share registrar : Hong Kong Branch Share Registrar
Tricor Investor Services Limited
Level 54, Hopewell Centre
183 Queen's Road East
Hong Kong

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 31 December 2021, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities.

SUFFICIENCY OF THE PUBLIC FLOAT

Based on the information publicly available to the Company and to the best knowledge, information and belief of the Directors, the Directors confirm that the Company had maintained a sufficient public float as required under the Listing Rules during the six months ended 31 December 2021.

On behalf of the Board
Dr. Sun Yiu Kwong
Chairman and Chief Executive Officer
Hong Kong, 24 February 2022

中期股息

董事會派付截至2021年12月31日止六個月的中期股息每股1.50港仙(2020年同期:1.00港仙)。

中期股息將派付予於2022年3月16日(星期三)名列本公司股東名冊上之本公司股東。預期中期股息將於2022年4月8日(星期五)或前後派付。

暫停辦理股份過戶手續

暫停辦理股份過戶 : 2022年3月14日(星期一)至
登記日期(首尾 2022年3月16日(星期三)
兩天包括在內)

股份過戶登記截止 : 2022年3月11日(星期五),
辦理股份過戶 下午四時三十分

股份過戶登記地點 : 香港股份過戶登記分處
卓佳證券登記有限公司
香港
皇后大道東183號
合和中心54樓

購買、出售或贖回本公司上市證券

截至2021年12月31日止六個月,本公司及本公司任何附屬公司概無購買、出售或贖回本公司任何上市證券。

足夠公眾持股量

就本公司所得之公開資料所示,並據董事所深知、所悉及所信,董事確認截至2021年12月31日止六個月本公司已維持上市規則所規定之充足公眾持股量。

代表董事會
孫耀江醫生
主席兼行政總裁
香港, 2022年2月24日

Condensed Consolidated Statement of Profit or Loss

簡明綜合損益表

Six months ended 31 December 2021
截至2021年12月31日止六個月

Six months ended 31 December
截至12月31日止六個月

		Notes 附註	2021 2021年 HK\$'000 千港元 (Unaudited) (未經審核)	2020 2020年 HK\$'000 千港元 (Unaudited) (未經審核) (Restated) (經重列)
Continuing operations	持續經營業務			
REVENUE	收入	5	358,210	299,221
Other income and gains	其他收入及收益	5	4,278	3,832
Professional services expenses	專業服務費用		(127,297)	(109,674)
Employee benefit expense	員工福利開支		(83,890)	(51,972)
Property rental and related expenses	物業租金及相關開支		(4,637)	(3,913)
Cost of inventories consumed	已耗存貨成本		(19,946)	(14,801)
Depreciation and amortisation	折舊及攤銷		(37,603)	(37,970)
Other expenses, net	其他支出淨額		(29,245)	(27,018)
Finance cost	融資成本		(1,834)	(1,804)
Share of profits of:	分佔利潤：			
Joint ventures	合資公司		618	-
Associates	聯營公司		1,501	1,182
PROFIT BEFORE TAX	除稅前利潤	6	60,155	57,083
Income tax expense	所得稅費用	7	(10,981)	(9,990)
PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	來自持續經營業務的期內利潤		49,174	47,093
Discontinued operation	已終止經營業務			
Profit/(loss) for the period from discontinued operation	已終止經營業務的期內利潤/(虧損)	8	1,197	(14,519)
PROFIT FOR THE PERIOD	期內利潤		50,371	32,574
Attributable to:	以下各方應佔：			
Owners of the Company	本公司擁有人			
From continuing operations	來自持續經營業務		44,661	42,694
From discontinued operation	來自已終止經營業務		1,666	(11,615)
			46,327	31,079
Non-controlling interests	非控股權益		4,044	1,495
			50,371	32,574
EARNINGS/(LOSS) PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY	本公司普通權益持有人應佔每股盈利/(虧損)	10		
Basic and diluted	基本及攤薄			
– Continuing operations	– 持續經營業務		HK5.835 cents港仙	HK5.640 cents港仙
– Discontinued operation	– 已終止經營業務		HK0.218 cents港仙	HK(1.535) cents港仙
Total – included discontinued operation	總額—包括已終止經營業務		HK6.053 cents港仙	HK4.105 cents港仙

Condensed Consolidated Statement of Comprehensive Income

簡明綜合全面收入表

Six months ended 31 December 2021
截至2021年12月31日止六個月

Six months ended 31 December
截至12月31日止六個月

2021	2020
2021年	2020年
HK\$'000	HK\$'000
千港元	千港元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)
	(Restated)
	(經重列)

PROFIT FOR THE PERIOD	期內利潤	50,371	32,574
OTHER COMPREHENSIVE INCOME/(LOSS)	其他全面收入／(虧損)		
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:	於其後期間可能重新分類至損益的其他全面收入／(虧損)：		
Exchange differences on translation of foreign operations	折算海外業務的匯兌差額	707	2,494
Release of reserve upon disposal of subsidiaries	因出售附屬公司而解除儲備	(1,786)	1,279
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	於其後期間可能重新分類至損益的其他全面收入／(虧損)淨額	(1,079)	3,773
Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods:	於其後期間不會重新分類至損益的其他全面收入／(虧損)：		
Changes in fair value of equity investments designated at fair value through other comprehensive income	指定為按公允價值計入其他全面收入之股本投資的公允價值變動	3,717	(2,411)
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	期內其他全面收入，扣除稅項	2,638	1,362
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	期內全面收入總額	53,009	33,936
Attributable to:	以下各方應佔：		
Owners of the Company	本公司擁有人	48,965	32,441
Non-controlling interests	非控股權益	4,044	1,495
		53,009	33,936

Condensed Consolidated Statement of Financial Position

簡明綜合財務狀況表

31 December 2021
2021年12月31日

			31 December 2021 2021年 12月31日 HK\$'000 千港元 (Unaudited) (未經審核)	30 June 2021 2021年 6月30日 HK\$'000 千港元 (Audited) (經審核)
NON-CURRENT ASSETS	非流動資產			
Property, plant and equipment	物業、廠房及設備	11	102,453	99,430
Right-of-use assets	使用權資產		87,765	73,666
Goodwill	商譽	12	164,768	164,768
Other intangible assets	其他無形資產		60,767	61,681
Investments in joint ventures	於合資公司的投資		8,589	7,970
Investments in associates	於聯營公司的投資		12,588	4,501
Financial assets at amortised cost	按攤銷成本計量的金融資產	13	6,385	19,025
Investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資	14	26,967	23,603
Deferred tax assets	遞延稅項資產		1,389	1,417
Deposits	保證金		19,175	20,544
Total non-current assets	非流動資產總額		490,846	476,605
CURRENT ASSETS	流動資產			
Inventories	存貨		10,479	9,198
Trade receivables	貿易應收款項	15	96,872	83,364
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產		30,478	18,088
Financial assets at fair value through profit or loss	按公允價值計入損益的金融資產		31,807	27,115
Financial assets at amortised cost	按攤銷成本計量的金融資產	13	26,613	14,046
Amounts due from associates	應收聯營公司款項		17,885	3,730
Amount due from a joint venture	應收一間合資公司款項		2,151	451
Amounts due from related companies	應收關聯公司款項		1,894	1,220
Tax recoverable	可收回稅項		69	551
Pledged deposits	抵押存款		2,393	1,893
Cash and cash equivalents	現金及現金等價物		259,410	293,974
Assets of disposal groups classified as held for sale	分類為持作出售組別之資產		480,051	453,630
			-	39,742
Total current assets	流動資產總額		480,051	493,372

Condensed Consolidated Statement of Financial Position

簡明綜合財務狀況表

31 December 2021
2021年12月31日

			31 December 2021 2021年 12月31日 HK\$'000 千港元 (Unaudited) (未經審核)	30 June 2021 2021年 6月30日 HK\$'000 千港元 (Audited) (經審核)
CURRENT LIABILITIES	流動負債			
Trade payables	貿易應付款項	16	44,243	62,185
Other payables and accruals	其他應付款項及應計費用		86,352	64,376
Amounts due to associates	應付聯營公司款項		117	-
Amounts due to related companies	應付關聯公司款項		2,269	5,618
Amount due to a joint venture	應付一間合資公司款項		875	561
Lease liabilities	租賃負債		44,368	38,731
Tax payable	應付稅項		22,088	26,848
			200,312	198,319
Liabilities associated with the disposal groups classified as held for sale	與分類為持作出售組別有關之負債		-	24,441
Total current liabilities	流動負債總額		200,312	222,760
NET CURRENT ASSETS	流動資產淨額		279,739	270,612
TOTAL ASSETS LESS CURRENT LIABILITIES	總資產減流動負債		770,585	747,217
NON-CURRENT LIABILITIES	非流動負債			
Lease liabilities	租賃負債		46,767	39,296
Deferred tax liabilities	遞延稅項負債		12,045	12,238
Provision	撥備		2,631	2,627
Total non-current liabilities	非流動負債總額		61,443	54,161
Net assets	資產淨額		709,142	693,056
EQUITY	權益			
Equity attributable to owners of the Company	本公司擁有人應佔權益			
Issued capital	已發行股本	17	775	775
Reserves	儲備		668,834	638,723
			669,609	639,498
Non-controlling interests	非控股權益		39,533	53,558
Total equity	權益總額		709,142	693,056

Condensed Consolidated Statement of Changes in Equity

簡明綜合權益變動表

Six months ended 31 December 2021
截至2021年12月31日止六個月

		Attributable to owners of the Company 本公司擁有人應佔											
		Issued capital	Share premium account	Capital contribution reserve	Shares held for the share award scheme	Share-based payment reserve	Fair value reserve	Legal reserve	Exchange fluctuation reserve	Retained profits	Total	Non-controlling interests	Total equity
		已發行股本	股份溢價賬	出資儲備	持有的股份	以股份為基礎支付的儲備	公允價值儲備	法定儲備	匯兌波動儲備	留存利潤	合計	非控股權益	權益總額
Notes		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
附註		千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元
At 30 June 2020 (audited)	於2020年6月30日(經審核)	766	397,612	37,294	(13,430)	45,151	(22,301)	1,364	(4,019)	169,409	611,846	58,661	670,507
Profit for the period	期內利潤	-	-	-	-	-	-	-	-	31,079	31,079	1,495	32,574
Other comprehensive income/(loss) for the period	期內其他全面收入/(虧損)	-	-	-	-	-	-	-	-	-	-	-	-
Changes in fair value of equity investments at fair value through other comprehensive income	按公允價值計入其他全面收入之股本投資的公允價值變動	-	-	-	-	-	(2,411)	-	-	-	(2,411)	-	(2,411)
Exchange differences on translation of foreign operations	折算海外業務的匯兌差額	-	-	-	-	-	-	-	2,494	-	2,494	-	2,494
Release of reserve upon disposal of subsidiaries	因出售附屬公司而解除儲備	-	-	-	-	-	-	-	1,279	-	1,279	-	1,279
Total comprehensive income/(loss) for the period	期內全面收入/(虧損)總額	-	-	-	-	-	(2,411)	-	3,773	31,079	32,441	1,495	33,936
Equity-settled arrangements	以權益結算之安排	-	-	-	-	709	-	-	-	-	709	-	709
Dividends paid to non-controlling interests	已付非控股權益的股息	-	-	-	-	-	-	-	-	-	-	(675)	(675)
Purchase of shares for the share award scheme	就股份獎勵計劃購買的股份	-	-	-	(170)	-	-	-	-	-	(170)	-	(170)
Final 2020 dividend	2020年末期股息	-	-	-	-	-	-	-	-	(20,293)	(20,293)	-	(20,293)
Transfer to legal reserve	轉撥至法定儲備	-	-	-	-	-	-	1,313	-	(1,313)	-	-	-
At 31 December 2020 (unaudited)	於2020年12月31日(未經審核)	766	397,612	37,294	(13,600)	45,860	(24,712)	2,677	(246)	178,882	624,533	59,481	684,014
At 30 June 2021 (audited)	於2021年6月30日(經審核)	775	409,015*	37,294*	(14,693)*	47,542*	(17,495)*	2,571*	(1,647)*	176,136*	639,498	53,558	693,056
Profit for the period	期內利潤	-	-	-	-	-	-	-	-	46,327	46,327	4,044	50,371
Other comprehensive income/(loss) for the period	期內其他全面收入/(虧損)	-	-	-	-	-	-	-	-	-	-	-	-
Changes in fair value of equity investments at fair value through other comprehensive income	按公允價值計入其他全面收入之股本投資的公允價值變動	-	-	-	-	-	3,717	-	-	-	3,717	-	3,717
Exchange differences on translation of foreign operations	折算海外業務的匯兌差額	-	-	-	-	-	-	-	707	-	707	-	707
Release of reserve upon disposal of subsidiaries	因出售附屬公司而解除儲備	-	-	-	-	-	-	-	(1,786)	-	(1,786)	-	(1,786)
Total comprehensive income/(loss) for the period	期內全面收入/(虧損)總額	-	-	-	-	-	3,717	-	(1,079)	46,327	48,965	4,044	53,009
Equity-settled arrangements	以權益結算之安排	-	-	-	-	2,622	-	-	-	-	2,622	-	2,622
Dividends paid to non-controlling interests	已付非控股權益的股息	-	-	-	-	-	-	-	-	-	-	(9,345)	(9,345)
Issue of shares under the share award scheme	根據股份獎勵計劃發行股份	-	-	-	279	-	-	-	-	-	279	-	279
Equity-settled share based payment arrangements	以權益結算的以股份為基礎的付款安排	-	-	-	-	(279)	-	-	-	-	(279)	-	(279)
Final 2021 dividend	2021年末期股息	-	-	-	-	-	-	-	-	(21,476)	(21,476)	-	(21,476)
Transfer to legal reserve	轉撥至法定儲備	-	-	-	-	-	-	23	-	(23)	-	-	-
Establishment of subsidiaries	成立附屬公司	-	-	-	-	-	-	-	-	-	-	316	316
Disposal of a subsidiary	出售附屬公司	-	-	-	-	-	-	-	-	-	-	(9,040)	(9,040)
At 31 December 2021 (unaudited)	於2021年12月31日(未經審核)	775	409,015*	37,294*	(14,414)*	49,885*	(13,778)*	2,594*	(2,726)*	200,964*	669,609	39,533	709,142

* These reserve accounts comprise the consolidated reserves of HK\$668,834,000 (30 June 2021: HK\$638,723,000) in the condensed consolidated statement of financial position.

* 該等儲備賬包括於簡明綜合財務狀況表內之綜合儲備668,834,000港元(2021年6月30日: 638,723,000港元)。

Condensed Consolidated Statement of Cash Flows

簡明綜合現金流量表

Six months ended 31 December 2021
截至2021年12月31日止六個月

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		Notes	
		附註	
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
			(Restated)
			(經重列)
CASH FLOWS FROM OPERATING ACTIVITIES	經營活動的現金流量		
Profit before tax	除稅前利潤	61,352	42,567
Total non-cash adjustments	非現金調整總額	26,841	47,928
Total working capital adjustments	營運資金調整總額	(35,957)	(37,455)
Cash generated from operations	經營業務產生的現金	52,236	53,040
Interest received	已收利息	54	84
Hong Kong profits tax paid	已付香港利得稅	(17,162)	(7,071)
Net cash flows from operating activities	經營活動產生的現金流量淨額	35,128	46,053
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動的現金流量		
Purchases of items of property, plant and equipment	購買物業、廠房及設備項目	11 (28,007)	(14,978)
Net outflow from disposal of subsidiaries	出售附屬公司的流出淨額	(386)	-
Purchases of debt investments at fair value through other comprehensive income	購買按公允價值計入其他全面收入的債務投資	-	(494)
Proceeds from redemption of financial assets at amortised cost	贖回按攤銷成本計量的金融資產所得款項	-	18,843
Purchase of investments at fair value through profit or loss	購買按公允價值計入損益的投資	(6,240)	(12,602)
Purchase of financial assets at amortised cost	購買按攤銷成本計量的金融資產	-	(12,989)
Dividend received from investments at fair value through other comprehensive income	已自按公允價值計入其他全面收入的投資之股息	5 2,188	-
Dividend received from investments at fair value through profit or loss	已自按公允價值計入損益的投資之股息	5 70	61
Other investing activities	其他投資活動	1,995	2,032
Net cash used in investing activities	投資活動使用的現金淨額	(30,380)	(20,127)

Condensed Consolidated Statement of Cash Flows

簡明綜合現金流量表

Six months ended 31 December 2021
截至2021年12月31日止六個月

Six months ended 31 December

截至12月31日止六個月

	2021	2020
	2021年	2020年
Notes	HK\$'000	HK\$'000
附註	千港元	千港元
	(Unaudited)	(Unaudited)
	(未經審核)	(未經審核)
		(Restated)
		(經重列)

CASH FLOWS FROM FINANCING ACTIVITIES	融資活動的現金流量		
Principal portion of lease payments	租賃付款的本金部分	(28,421)	(21,612)
Dividend paid to non-controlling interests	已付非控股權益股息	(9,345)	(674)
Other financing activities	其他融資活動	(1,983)	(170)
Net cash flows used in financing activities	融資活動使用的現金流量淨額	(39,749)	(22,456)
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物(減少)/增加淨額	(35,001)	3,470
Effect of foreign exchange rate changes, net	外匯匯率變動之影響(淨額)	437	875
Cash and cash equivalents at beginning of period	期初現金及現金等價物	293,974	230,671
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末現金及現金等價物	259,410	235,016
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS	現金及現金等價物結餘分析		
Cash and bank balances	現金及銀行存款	259,410	235,016

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

1. CORPORATE AND GROUP INFORMATION

UMP Healthcare Holdings Limited is a limited liability company incorporated in the Cayman Islands. The principal place of business of the Company is located at 27/F., Wing On House, 71 Des Voeux Road Central, Hong Kong.

During the period, the Group was principally engaged in the provision of healthcare services which include:

- corporate healthcare solution services;
- medical and dental services;
- medical imaging and laboratory services;
- other auxiliary medical services; and
- healthcare management services.

The shares of the Company were listed on the Main Board of the Hong Kong Stock Exchange on 27 November 2015 (the "Listing").

2. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements of the Group for the six months ended 31 December 2021 have been prepared in accordance with the Hong Kong Accounting Standard ("HKAS") 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). They have been prepared under the historical cost convention, except for equity investments, debt investments and a contingent consideration receivable which have been measured at fair value. The unaudited condensed consolidated financial statements are presented in Hong Kong dollars and all values are rounded to the nearest thousand except when otherwise indicated.

The unaudited condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 30 June 2021.

1. 公司及集團資料

聯合醫務集團有限公司為在開曼群島註冊成立的有限責任公司。本公司主要營業地點為香港德輔道中71號永安集團大廈27樓。

於本期間，本集團的主要業務為提供醫療保健服務，包括：

- 企業醫療保健解決方案服務；
- 醫療及牙科服務；
- 醫學影像及化驗服務；
- 其他輔助醫療服務；及
- 醫療保健管理服務。

本公司股份於2015年11月27日在香港聯交所主板上市（「上市」）。

2. 編製基準

本集團截至2021年12月31日止六個月之未經審核簡明綜合財務報表乃根據香港會計師公會（「香港會計師公會」）頒佈的香港會計準則（「香港會計準則」）第34號「中期財務報告」而編製。除以公允價值計量的股本投資、債務投資以及應收或有代價外，未經審核簡明綜合財務報表已根據歷史成本法編製。未經審核簡明綜合財務報表以港元呈列，且除另有指明者外，所有金額均四捨五入至最接近的千位數。

未經審核簡明綜合財務報表並不包括年度財務報表所需的所有資料及披露，並應與本集團截至2021年6月30日止年度之年度綜合財務報表一併閱讀。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the unaudited condensed consolidated financial statements of the Group for the six months ended 31 December 2021 are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 30 June 2021, except for the adoption of the following new and revised Hong Kong Financial Reporting Standards ("HKFRSs"), which are effective for the Group's annual period beginning on 1 July 2021.

- Amendment to HKFRS 16, Covid-19-related rent concessions beyond 30 June 2021
- Amendments to HKFRS 9, HKAS 39, HKFRS 7, HKFRS 4 and HKFRS 16, Interest rate benchmark reform - phase 2

Other than the amendment to HKFRS 16, the Group has not applied any new standard or interpretation that is not yet effective for the current accounting period. Impacts of the adoption of the amended HKFRSs are discussed below:

3. 會計政策及披露變動

編製本集團截至2021年12月31日止六個月之未經審核簡明綜合財務報表所採用的會計政策與編製本集團截至2021年6月30日止年度之年度綜合財務報表所採用者一致，惟採納以下於本集團於2021年7月1日開始之年度期間生效之新訂及經修訂香港財務報告準則（「香港財務報告準則」）除外。

- 香港財務報告準則第16號之修訂2021年6月30日後新型冠狀病毒病之相關租金減免
- 香港財務報告準則第9號、香港會計準則第39號、香港財務報告準則第7號、香港財務報告準則第4號及香港財務報告準則第16號之修訂利率基準改革－第二階段

除香港財務報告準則第16號之修訂外，本集團並無採用任何於本會計期間尚未生效之新準則或詮釋。採納經修訂香港財務報告準則之影響論述如下：

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

Amendment to HKFRS 16, *Covid-19-related rent concessions beyond 30 June 2021 (2021 amendment)*

The Group previously applied the practical expedient in HKFRS 16 such that as lessee it was not required to assess whether rent concessions occurring as a direct consequence of the COVID-19 pandemic were lease modifications, if the eligibility conditions are met. One of these conditions requires the reduction in lease payments affect only payments originally due on or before a specified time limit. The 2021 amendment extends this time limit from 30 June 2021 to 30 June 2022.

With the extended time limit, certain rent concessions that were previously ineligible for the practical expedient because of the original time limit, become eligible. Accordingly, these rent concessions, which were previously accounted for as lease modifications, are now accounted for as negative variable lease payments, and are recognised in profit or loss in the period in which the event or condition that triggers those payments occurred. There is no impact on the opening balance of equity at 1 July 2021.

Amendments to HKFRS 9, HKAS 39, HKFRS 7, HKFRS 4 and HKFRS 16, *Interest rate benchmark reform – phase 2*

The amendments provide targeted reliefs from (i) accounting for changes in the basis for determining contractual cash flows of financial assets, financial liabilities and lease liabilities as modifications, and (ii) discontinuing hedge accounting when an interest rate benchmark is replaced by an alternative benchmark rate as a result of the reform of interbank offered rates (“IBOR reform”). The amendments do not have an impact on this interim financial report as the Group does not have contracts that are indexed to benchmark interest rates which are subject to the IBOR reform.

3. 會計政策及披露變動 (續)

香港財務報告準則第16號之修訂2021年6月30日後新型冠狀病毒病之相關租金減免(2021年修訂)

本集團此前已應用香港財務報告準則第16號中的實際權宜安排，因此作為承租人，倘若符合資格條件，則毋須評估因新型冠狀病毒病疫情而直接導致的租金減免是否屬於租賃修改。其中一項條件要求租賃付款額的減少僅影響在指定期限內或之前到期的原付款額。2021年之修訂將此時限自2021年6月30日延長至2022年6月30日。

因應延長時限，之前因原本時限而不符合實際權宜安排的若干租金減免變得符合資格。因此，原本作為租賃修改入賬的該等租金減免現作為負可變租賃付款入賬，並在觸發該等付款的事件或條件發生期間於損益中確認。2021年7月1日的權益期初結餘概無受影響。

香港財務報告準則第9號、香港會計準則第39號、香港財務報告準則第7號、香港財務報告準則第4號及香港財務報告準則第16號之修訂利率基準改革—第二階段

該等修訂就以下各項提供針對性之寬免：(i)作為修訂對金融資產、金融負債及租賃負債的合約現金流量釐定基準之變動進行會計處理；及(ii)當銀行同業拆息改革(「銀行同業拆息改革」)導致利率基準被替代基準利率取代時，終止對沖會計處理。由於本集團並無受銀行同業拆息改革影響而與基準利率掛鈎的合約，故該等修訂概無對本中期財務報告造成影響。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

4. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has three reportable operating segments as follows:

- (a) Hong Kong & Macau Corporate Healthcare Solution Services segment engages in the provision of corporate healthcare solutions to contract customers in Hong Kong and Macau;
- (b) Hong Kong & Macau Clinical Healthcare Services segment engages in the provision of medical and dental services, health check-up and other auxiliary services in Hong Kong and Macau; and
- (c) Mainland China Clinical Healthcare Business segment engages in the provision of health check-up service and selected outpatient services in Mainland China.

Management monitors the results of the Group's operating segments separately for the purpose of facilitating decision-making process of resources allocation and performance assessment. Segment performance is evaluated based on reportable segment profit/loss, which is a measurement of adjusted profit before tax. The adjusted profit before tax is measured consistently with the Group's profit before tax excluding interest income, other income and gains, and share of profits and losses of joint ventures and associates as well as head office and corporate expenses.

Inter-segment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

4. 經營分部資料

就管理而言，本集團基於其產品及服務組織業務單位運營，且有如下三個可呈報經營分部：

- (a) 香港及澳門企業醫療保健解決方案服務分部為位於香港及澳門的合約客戶提供企業醫療保健解決方案；
- (b) 香港及澳門臨床醫療保健服務分部包括於香港及澳門提供醫療及牙科服務、健康檢查及其他輔助服務；及
- (c) 中國內地臨床醫療保健業務分部為在中國內地提供體檢服務及選定門診服務。

管理層分別監控本集團各經營分部的業績，以利便資源分配及業績評估的決策流程。分部業績基於可呈報分部利潤／虧損評估，為經調整除稅前利潤的計量方法。經調整除稅前利潤按與本集團除稅前利潤一致的方式計量，當中不包括利息收入、其他收入及收益、分佔合資公司及聯營公司損益以及總辦事處及公司開支。

分部間銷售及轉讓乃參考按當時現行市價向第三方銷售的售價處理。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

4. OPERATING SEGMENT INFORMATION

(Continued)

(a) Revenue and results

4. 經營分部資料(續)

(a) 收入及業績

		Continuing Operations 持續經營業務					
		Hong Kong and Macau 香港及澳門		Mainland China 中國內地			
		Corporate Healthcare Solution Services 企業 醫療保健 解決方案服務 HK\$'000 千港元	Clinical Healthcare Services 臨床醫療 保健服務 HK\$'000 千港元	Clinical Healthcare Business 臨床醫療 保健業務 HK\$'000 千港元	Continuing Operations Sub-total 持續經營業務 小計 HK\$'000 千港元	Discontinued Operation 已終止 經營業務 HK\$'000 千港元	Total 總計 HK\$'000 千港元
Six months ended 31 December 2021 (unaudited)	截至2021年12月31日止 六個月(未經審核)						
Segment revenue:	分部收入:						
External sales	外部銷售	123,517	211,988	22,705	358,210	6,099	364,309
Inter-segment sales	分部間銷售	973	60,999	-	61,972	-	61,972
		124,490	272,987	22,705	420,182	6,099	426,281
<i>Reconciliation:</i>	<i>調節:</i>						
Elimination of inter-segment sales	分部間銷售抵銷				(61,972)	-	(61,972)
Revenue	收入				358,210	6,099	364,309
Segment results	分部業績	19,386	51,843	529	71,758	1,197	72,955
<i>Reconciliation:</i>	<i>調節:</i>						
Interest income	利息收入						982
Other income and gains	其他收入及收益						3,796
Share of profits and losses of:	分佔利潤及虧損:						
Joint ventures	合資公司						618
Associates	聯營公司						1,501
Corporate and other unallocated expenses, net	公司及其他未分配開支淨額						(18,500)
Profit before tax	除稅前利潤						61,352
Income tax expense	所得稅費用						(10,981)
Profit for the period	期內利潤						50,371

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

4. OPERATING SEGMENT INFORMATION

(Continued)

(a) Revenue and results (Continued)

4. 經營分部資料(續)

(a) 收入及業績(續)

		Continuing Operations 持續經營業務							
		Hong Kong and Macau 香港及澳門		Mainland China 中國內地					
		Corporate Healthcare Solution Services 企業 醫療保健 解決方案服務 HK\$'000 千港元 (Restated) (經重列)	Clinical Healthcare Services 臨床醫療 保健服務 HK\$'000 千港元 (Restated) (經重列)	Clinical Healthcare Business 臨床醫療 保健業務 HK\$'000 千港元 (Restated) (經重列)	Continuing Operations Sub-total 持續 經營業務小計 HK\$'000 千港元 (Restated) (經重列)	Discontinued Operation 已終止 經營業務 HK\$'000 千港元 (Restated) (經重列)	Total 總計 HK\$'000 千港元 (Restated) (經重列)		
Six months ended	截至2020年12月31日止								
31 December 2020 (unaudited)	六個月(未經審核)								
Segment revenue:	分部收入:								
External sales	外部銷售	121,615	160,122	17,484	299,221	2,922	302,143		
Inter-segment sales	分部間銷售	660	52,932	-	53,592	-	53,592		
		122,275	213,054	17,484	352,813	2,922	355,735		
<i>Reconciliation:</i>	<i>調節:</i>								
Elimination of inter-segment sales	分部間銷售抵銷						(53,592)	-	(53,592)
Revenue	收入						299,221	2,922	302,143
Segment results	分部業績	32,956	38,910	(8,229)	63,637	(14,519)	49,118		
<i>Reconciliation:</i>	<i>調節:</i>								
Interest income	利息收入							1,545	
Other income and gains	其他收入及收益							2,268	
Share of profits and losses of:	分佔利潤及虧損:								
Joint ventures	合資公司							-	
Associates	聯營公司							1,182	
Corporate and other unallocated expenses, net	公司及其他未分配開支淨額							(11,549)	
Profit before tax	除稅前利潤							42,564	
Income tax expense	所得稅費用							(9,990)	
Profit for the period	期內利潤							32,574	

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

4. OPERATING SEGMENT INFORMATION

(Continued)

(b) Information about major customers

Revenue from a major customer which accounted for 10% or more of the Group's revenue from the Corporate Healthcare Solution Services to Contract Customers segment is set out below:

Customer A	客戶A	20,409	20,654
Customer B	客戶B	20,099	19,247

4. 經營分部資料(續)

(b) 主要客戶資料

來自一名主要客戶(佔本集團來自向合約客戶提供企業醫療保健解決方案服務分部的收入的10%或以上的客戶)的收入載列如下:

Six months ended 31 December

截至12月31日止六個月

2021	2020
2021年	2020年
HK\$'000	HK\$'000
千港元	千港元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

Customer A	客戶A	20,409	20,654
Customer B	客戶B	20,099	19,247

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

5. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue from continuing operations is as follows:

Disaggregated revenue information from continuing operations

Six months ended 31 December 2021

5. 收入、其他收入及收益

來自持續經營業務的收入之分析如下：

經分拆之來自持續經營業務的收入之資料

截至2021年12月31日止六個月

		Six months ended 31 December		Increase/ (decrease)
		截至12月31日止六個月		
		2021	2020	增加／ (減少)
		2021年	2020年	
		HK\$'000	HK\$'000	
		千港元	千港元	
		(Unaudited)	(Unaudited)	
		(未經審核)	(未經審核)	
			(Restated)	
			(經重列)	
Provision of corporate healthcare solution services in Hong Kong and Macau	於香港及澳門提供企業醫療保健解決方案服務	123,517	121,615	1.6%
Medical	醫療	112,435	109,815	2.4%
Dental	牙科	11,082	11,800	(6.1%)
Provision of clinical healthcare services in Hong Kong and Macau	於香港及澳門提供臨床醫療保健服務	211,988	160,122	32.4%
Medical	醫療	181,567	132,666	36.9%
Dental	牙科	30,421	27,456	10.8%
Mainland China Clinical Healthcare Business	中國內地臨床醫療保健業務	22,705	17,484	29.9%
TOTAL	合計	358,210	299,221	19.7%

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

5. REVENUE, OTHER INCOME AND GAINS

(Continued)

An analysis of other income and gains from continuing operations is as follows:

5. 收入、其他收入及收益 (續)

來自持續經營業務的其他收入及收益的分析如下：

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
			(Restated)
			(經重列)
Other income and gains	其他收入及收益		
Administrative support fees	行政支援費用	317	341
Bank interest income	銀行利息收入	49	12
Interest income on financial assets at amortised cost	按攤銷成本計量的金融資產的利息收入	928	1,345
Interest income on investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資的利息收入	–	189
Dividend income from investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資的股息收入	2,188	–
Dividend income from financial assets at fair value through profit or loss	按公允價值計入損益的金融資產的股息收入	70	61
Gain on disposal of subsidiaries	出售附屬公司的收益	459	–
Others	其他	267	1,884
		4,278	3,832

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

6. PROFIT BEFORE TAX

The Group's profit before tax from continuing operations is arrived at after charging/(crediting):

6. 除稅前利潤

本集團來自持續經營業務的除稅前利潤乃扣除／（計入）下列各項後得出：

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
			(Restated)
			(經重列)
Amortisation of intangible assets	無形資產攤銷	1,155	1,203
Depreciation of property, plant and equipment	物業、廠房及設備折舊	9,097	11,344
Depreciation of right-of-use assets	使用權資產折舊	27,351	25,423
Equity-settled share-based payment expense (including employees and professional consultants)	以權益結算以股份為基礎的付款開支（包括僱員及專業顧問）	2,622	709
Fair value (gain)/loss on financial assets at fair value through profit or loss	按公允價值計入損益的金融資產的公允價值（收益）／虧損	1,547	(197)
Foreign exchange differences, net	匯兌差額淨值	79	(103)
(Gain)/Loss on disposal of subsidiaries	出售附屬公司的（收益）／虧損	(459)	452*
Write-off of items of property, plant and equipment	撇銷物業、廠房及設備項目	47	-
Impairment of other assets	其他資產之減值	-	4,082
Impairment of deposit	按金之減值	-	4,146

* The loss on disposal of subsidiaries above is excluded in note 5 "Revenue, other income and gains".

* 上列的出售附屬公司的虧損並不包括在附註5「收入、其他收入及收益」之內。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

7. INCOME TAX

Hong Kong profits tax has been provided at the rate of 16.5% (six months ended 31 December 2020: 16.5%) on the estimated assessable profits arising in Hong Kong during the period. Taxes on profits assessable elsewhere have been calculated at the rates of tax prevailing in the countries/jurisdictions in which the Group operates.

The amount of income tax from continuing operations charged to condensed consolidated statement of profit or loss represents:

7. 所得稅

香港利得稅已於期內對香港產生的估計應課稅利潤按16.5%（截至2020年12月31日止六個月：16.5%）的稅率計提撥備。其他地區應課稅利潤的稅項按本集團業務所在國家／司法權區的現行稅率計算。

於簡明綜合損益表扣除的來自持續經營業務之所得稅金額代表：

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
			(Restated)
			(經重列)
Current – Hong Kong	即期 – 香港		
Charge for the period	期內支出	10,619	10,231
Current – Mainland China/Macau	即期 – 中國內地／澳門		
Charge for the period	期內支出	567	263
Deferred	遞延	(205)	(504)
Total tax charge for the period	期內稅項支出總額	10,981	9,990

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

8. DISCONTINUED OPERATION

On 31 December 2021, 55% shareholding of UMP Healthcare China Limited (“UMP Healthcare China”), an indirect non-wholly owned subsidiary of the Company, was disposed at a consideration of HK\$22 million. Subsequent to the transaction, the Group’s shareholding in UMP Healthcare China decreased from 80% to 25% and the Group ceased control over UMP Healthcare China. As a result, UMP Healthcare China and its subsidiaries have become the associates of the Group. As the disposed business is considered as a major line of business, the corresponding operation had been classified as a discontinued operation as a result of the completion of disposal.

The results of these discontinued operation for the six month period ended 31 December 2021 and 2020 are set out below:

8. 已終止經營業務

於2021年12月31日，本公司間接非全資附屬公司聯合醫務中國有限公司（「聯合醫務中國」）的55%股權以22百萬港元的代價出售。交易完成後，本集團在聯合醫務中國的持股比例從80%降至25%而本集團不再控制聯合醫務中國。因此，聯合醫務中國及其附屬公司已成為本集團的聯營公司。由於所出售的業務被認為是主要的業務線，相應的業務在出售完成後已分類為已終止經營業務。

截至2021年及2020年12月31日止六個月期間，此等已終止經營業務的業績如下：

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
REVENUE	收入	6,099	2,922
Other income and gains	其他收入及收益	5,379	16
Professional services expenses	專業服務費用	(3,571)	(1,091)
Employee benefit expense	員工福利開支	(9,374)	(8,073)
Property rental and related expenses	物業租金及相關開支	–	(216)
Cost of inventories consumed	已耗存貨成本	(362)	(206)
Depreciation and amortisation	折舊及攤銷	(4,212)	(2,462)
Other expenses, net	其他支出淨額	(8,025)	(5,234)
Finance cost	融資成本	(149)	(172)
LOSS BEFORE TAX	除稅前虧損	(14,215)	(14,516)
Income tax expense	所得稅費用	–	(3)
		(14,215)	(14,519)
Gain on disposal of discontinued operation	出售已終止經營業務的收益	15,412	–
PROFIT/(LOSS) FOR THE PERIOD FROM DISCONTINUED OPERATION	已終止經營業務的期內利潤／(虧損)	1,197	(14,519)

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

8. DISCONTINUED OPERATION (Continued) Total comprehensive income from discontinued operation

8. 已終止經營業務(續) 已終止經營業務之全面收入總額

		Six months ended 31 December 截至12月31日止六個月	
		2021 2021年 HK\$'000 千港元 (unaudited) (未經審核)	2020 2020年 HK\$'000 千港元 (unaudited) (未經審核)
PROFIT/(LOSS) FOR THE PERIOD FROM DISCONTINUED OPERATION	已終止經營業務的期內利潤/(虧損)	1,197	(14,519)
OTHER COMPREHENSIVE INCOME/(LOSS)	其他全面收入/(虧損)		
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:	於其後期間可能重新分類至損益的其他全面收入/(虧損)：		
Exchange differences on translation of foreign operations	折算海外業務的匯兌差額	(692)	710
Release of reserve upon disposal of subsidiaries	因出售附屬公司而解除儲備	(1,786)	-
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	期內其他全面收入/(虧損)，扣除稅項	(2,478)	710
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	期內全面虧損總額	(1,281)	(13,809)
Attributable to:	以下各方應佔：		
Owners of the Company	本公司擁有人	(812)	(10,905)
Non-controlling interests	非控股權益	(469)	(2,904)
		(1,281)	(13,809)

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

8. DISCONTINUED OPERATION (Continued)

The disposal was completed on 31 December 2021. The carrying amounts of assets and liabilities as at 31 December 2021, the disposal date, were as follow:

8. 已終止經營業務(續)

出售已於2021年12月31日完成。資產及負債於2021年12月31日(出售日期)的賬面值如下：

		HK\$'000 千港元 (unaudited) (未經審核)
Property, plant and equipment	物業、廠房及設備	15,342
Right-of-use assets	使用權資產	5,534
Investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資	494
Deposits	保證金	2,101
Inventories	存貨	167
Trade receivables	貿易應收款項	1,585
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	1,272
Cash and cash equivalents	現金及現金等價物	24,349
Trade payables	貿易應付款項	(2,191)
Other payables and accruals	其他應付款項及應計費用	(4,962)
Lease liabilities	租賃負債	(6,121)
Amounts due to related companies	應付關聯公司款項	(17,143)
Non-controlling interest	非控股權益	(4,086)
		16,341
Gain on disposal	出售之收益	15,412
Release of reserve upon disposal	因出售而解除儲備	(1,786)
		29,967
Represented by:	代表：	
Cash consideration received	已收現金代價	22,000
Fair value of the Group's existing shareholding	本集團現有股權的公允價值	7,967
		29,967

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

8. DISCONTINUED OPERATION (Continued)

Analysis of net outflow of cash and cash equivalents in respect of the disposal of subsidiaries as at 31 December 2021, the disposal date were as follows:

		HK\$'000
		千港元
		(unaudited)
		(未經審核)
Satisfied by:	以下列方式支付：	
Cash consideration received	已收現金代價	22,000
Cash and cash equivalents disposed of	已出售的現金及現金等價物	(24,349)
Net outflow of cash and cash equivalents in respect of the disposal of subsidiaries	有關出售附屬公司的現金及現金等價物的流出淨額	(2,349)

8. 已終止經營業務(續)

於2021年12月31日(出售日期)有關出售附屬公司的現金及現金等價物的流出淨額之分析如下：

Cash flows from discontinued operation

已終止經營業務的現金流量

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Net cash used in operating activities	經營活動所用現金淨額	(5,922)	(2,573)
Net cash used in investing activities	投資活動所用現金淨額	(5,415)	(5,291)
Net cash used in financing activities	融資活動所用現金淨額	(2,337)	(1,953)
Net cash used in discontinued operation	已終止經營業務所用現金淨額	(13,674)	(9,817)

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

9. DIVIDENDS

9. 股息

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Dividend recognised as distribution during the period:	期內確認為分派之股息：		
Final dividend for the year ended 30 June 2021:	截至2021年6月30日止年度之末期股息：		
HK2.80 cents (year ended 30 June 2020: HK2.65 cents) per ordinary share	每股普通股2.80港仙(截至2020年6月30日止年度：2.65港仙)	21,476	20,293
Dividend proposed after the end of the reporting period:	報告期末後擬派股息：		
Interim dividend for the six months ended 31 December 2021:	截至2021年12月31日止六個月之中期股息：		
HK1.50 cent (six months ended 31 December 2020: HK1.00 cent) per ordinary share	每股普通股1.50港仙(截至2020年12月31日止六個月：1.00港仙)	11,890	7,754

The proposed interim dividend of HK1.50 cent per ordinary share in respect of the year ending 30 June 2022 was approved by the board of directors on 24 February 2022. The interim dividend of HK1.00 cent per ordinary share in respect of the year ended 30 June 2021 was approved by the board of directors on 25 February 2021.

The final dividend of HK2.80 cents per ordinary share, with a scrip dividend alternative, in respect of the year ended 30 June 2021 was approved by the Company's shareholders at the annual general meeting held on 26 November 2021. The final dividend of HK2.65 cents per ordinary share in respect of year ended 30 June 2020 was approved by the Company's shareholders at the annual general meeting held on 20 November 2020.

有關截至2022年6月30日止年度之擬派中期股息每股普通股1.50港仙於2022年2月24日獲董事會批准。有關截至2021年6月30日止年度之中期股息每股普通股1.00港仙於2021年2月25日獲董事會批准。

有關截至2021年6月30日止年度之末期股息每股普通股2.80港仙(連同以股代息選項)於2021年11月26日舉行之股東週年大會上獲本公司股東批准。有關截至2020年6月30日止年度之末期股息每股普通股2.65港仙於2020年11月20日舉行之股東週年大會上獲本公司股東批准。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY

The calculation of the basic earnings per share amount is based on the unaudited consolidated profit for the six months ended 31 December 2021 attributable to ordinary equity holders of the Company of HK\$46,327,000 (six months ended 31 December 2020: HK\$31,079,000), and the weighted average number of ordinary shares of 765,417,711 (six months ended 31 December 2020: 757,019,355) in issue which have excluded the shares held under the share award scheme during the period.

The calculation of the diluted earnings per share amount is based on the unaudited consolidated profit for the six months ended 31 December 2021 attributable to ordinary equity holders of the Company of HK\$46,327,000. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares of 765,417,711 in issue during the period and excluded the shares held under the share award scheme, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares of nil assumed to have been issued at no consideration on the deemed exercise of all share options and shares under the share award scheme into ordinary shares.

The calculation of the diluted earnings per share amount is based on the unaudited consolidated profit for the six months ended 31 December 2020 attributable to ordinary equity holders of the Company of HK\$31,079,000. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares of 757,019,355 in issue during the period and excluded the shares held under the share award scheme, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares of 102,542 assumed to have been issued at no consideration on the deemed exercise of all share options and shares under the share award scheme into ordinary shares.

10. 本公司普通權益持有人應佔每股盈利

截至2021年12月31日止六個月之每股基本盈利金額乃基於期內本公司普通權益持有人應佔未經審核綜合利潤46,327,000港元(截至2020年12月31日止六個月: 31,079,000港元)及期內已發行普通股加權平均股數765,417,711股(截至2020年12月31日止六個月: 757,019,355股)(此並不包括股份獎勵計劃項下預留的股份)計算。

截至2021年12月31日止六個月之每股攤薄盈利金額乃基於期內本公司普通權益持有人應佔未經審核綜合利潤46,327,000港元。計算所用的普通股加權平均股數為計算每股基本盈利所用的期內已發行765,417,711股普通股，並不包括股份獎勵計劃項下預留的股份，以及假設於所有購股權及股份獎勵計劃項下股份被視為已行使為普通股時，按無償方式發行的普通股加權平均股數為無。

截至2020年12月31日止六個月之每股攤薄盈利金額乃基於期內本公司普通權益持有人應佔未經審核綜合利潤31,079,000港元。計算所用的普通股加權平均股數為計算每股基本盈利所用的期內已發行757,019,355股普通股，並不包括股份獎勵計劃項下預留的股份，以及假設於所有購股權及股份獎勵計劃項下股份被視為已行使為普通股時，按無償方式發行的普通股加權平均股數102,542股。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

11. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 31 December 2021, additions of property, plant and equipment amounted to HK\$28,007,000 (six months ended 31 December 2020: HK\$14,978,000).

12. GOODWILL

11. 物業、廠房及設備

於截至2021年12月31日止六個月期間，添置物業、廠房及設備項目為28,007,000港元（截至2020年12月31日止六個月：14,978,000港元）。

12. 商譽

		31 December 2021 2021年 12月31日 HK\$'000 千港元 (Unaudited) (未經審核)	30 June 2021 2021年 6月30日 HK\$'000 千港元 (Audited) (經審核)
At end of period/year	期/年末	164,768	164,768

13. FINANCIAL ASSETS AT AMORTISED COST

		31 December 2021 2021年 12月31日 HK\$'000 千港元 (Unaudited) (未經審核)	30 June 2021 2021年 6月30日 HK\$'000 千港元 (Audited) (經審核)
Financial assets at amortised cost	金融資產，按攤銷成本計量	32,998	33,071
Analysed into:	分析作：		
Non-current portion	非即期部分	6,385	19,025
Current portion	即期部分	26,613	14,046
		32,998	33,071

13. 按攤銷成本計量的金融資產

As at 31 December 2021, the Group's financial assets at amortised cost have fixed maturity dates between 2022 and 2023 and fixed interest rates ranging from 4.25% to 8.50% per annum (30 June 2021: 4.25% to 8.50% per annum).

於2021年12月31日，本集團按攤銷成本計量的金融資產具有在2022年至2023年之間的固定到期日，定息年利率介乎4.25%至8.50%（2021年6月30日：年利率介乎4.25%至8.50%）。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

14. INVESTMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

14. 按公允價值計入其他全面收入的投資

		31 December 2021 2021年 12月31日 HK\$'000 千港元 (Unaudited) (未經審核)	30 June 2021 2021年 6月30日 HK\$'000 千港元 (Audited) (經審核)
Investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資		
Unlisted equity investments, at fair value	非上市股本投資，按公允價值計量	4,901	5,367
Listed equity investments, at fair value	上市股本投資，按公允價值計量	22,066	18,236
		26,967	23,603

The above investments were designated at fair value through other comprehensive income as the Group considers these investments to be strategic in nature.

During the period, the Group received dividends in the approximate amounts of nil (30 June 2021: nil) and HK\$2,258,000 (30 June 2021: HK\$85,000) from an unlisted equity investment and a listed equity investment, respectively.

以上投資已指定為按公允價值計入其他全面收入，因為本集團認為此等投資在性質上屬策略投資。

於期內，本集團從一項非上市股本投資及一項上市股本投資收取金額分別約為零港元（2021年6月30日：零港元）及2,258,000港元（2021年6月30日：85,000港元）的股息。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

15. TRADE RECEIVABLES

15. 貿易應收款項

		31 December	30 June
		2021	2021
		2021年	2021年
		12月31日	6月30日
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Audited)
		(未經審核)	(經審核)
Trade receivables	貿易應收款項	96,872	83,364

The Group's trading terms with its contract customers are mainly on credit. The credit period is generally one month, extending up to two months for major customers. Each contract customer has a maximum credit limit. The Group seeks to maintain strict control over its outstanding receivables and has a designated policy to monitor and minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An aging analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

本集團與其合約客戶之貿易條款主要以信貸方式進行。信貸期一般為1個月，對主要客戶可延長至2個月。每名合約客戶均設有最高信用額度。本集團力求對未償還應收款項維持嚴格控制，並設有指定政策，以監測並將信貸風險減至最低。逾期結餘由高級管理層定期審閱。本集團並無就該等貿易應收款項餘額持有任何抵押品或其他信貸提升保障。貿易應收款項不計息。

於報告期末的貿易應收款項按發票日期及扣除虧損撥備的賬齡分析如下：

		31 December	30 June
		2021	2021
		2021年	2021年
		12月31日	6月30日
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Audited)
		(未經審核)	(經審核)
Within 1 month	1個月內	56,193	50,580
1 to 2 months	1至2個月	18,833	13,710
2 to 3 months	2至3個月	11,612	6,230
Over 3 months	3個月以上	10,234	12,844
		96,872	83,364

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

16. TRADE PAYABLES

An aging analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

		31 December	30 June
		2021	2021
		2021年	2021年
		12月31日	6月30日
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Audited)
		(未經審核)	(經審核)
Within 1 month	1個月內	29,293	37,560
1 to 3 months	1至3個月	14,671	23,860
Over 3 months	3個月以上	279	765
		44,243	62,185

The trade payables are non-interest-bearing and are normally settled on terms of ranging from 30 to 90 days.

16. 貿易應付款項

於報告期末的貿易應付款項按發票日期的賬齡分析如下：

		31 December	30 June
		2021	2021
		2021年	2021年
		12月31日	6月30日
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Audited)
		(未經審核)	(經審核)
Within 1 month	1個月內	29,293	37,560
1 to 3 months	1至3個月	14,671	23,860
Over 3 months	3個月以上	279	765
		44,243	62,185

貿易應付款項為免息且一般於30天至90天內結算。

17. SHARE CAPITAL

		31 December	30 June
		2021	2021
		2021年	2021年
		12月31日	6月30日
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Audited)
		(未經審核)	(經審核)
Authorised:	法定：		
5,000,000,000 (30 June 2021: 5,000,000,000) ordinary shares of HK\$0.001 (30 June 2021: HK\$0.001) each	5,000,000,000股(2021年6月30日：5,000,000,000股)每股面值0.001港元(2021年6月30日：0.001港元)的普通股	5,000	5,000
Issued and fully paid:	已發行及繳足：		
775,350,089 (30 June 2021: 775,350,089) ordinary shares of HK\$0.001 (30 June 2021: HK\$0.001) each	775,350,089股(2021年6月30日：775,350,089股)每股面值0.001港元(2021年6月30日：0.001港元)的普通股	775	775

17. 股本

		31 December	30 June
		2021	2021
		2021年	2021年
		12月31日	6月30日
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Audited)
		(未經審核)	(經審核)
Authorised:	法定：		
5,000,000,000 (30 June 2021: 5,000,000,000) ordinary shares of HK\$0.001 (30 June 2021: HK\$0.001) each	5,000,000,000股(2021年6月30日：5,000,000,000股)每股面值0.001港元(2021年6月30日：0.001港元)的普通股	5,000	5,000
Issued and fully paid:	已發行及繳足：		
775,350,089 (30 June 2021: 775,350,089) ordinary shares of HK\$0.001 (30 June 2021: HK\$0.001) each	775,350,089股(2021年6月30日：775,350,089股)每股面值0.001港元(2021年6月30日：0.001港元)的普通股	775	775

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

17. SHARE CAPITAL (Continued)

The movements in the Company's authorised and issued share capital during the period from 1 July 2020 to 31 December 2021 are as follows:

		Number of ordinary shares 普通股數目	Nominal value of ordinary shares 普通股面值 HK\$'000 千港元
	Note 附註		
Authorised:	法定：		
At 1 July 2020, at 31 December 2020, at 30 June 2021, at 1 July 2021 and at 31 December 2021	於2020年7月1日、於2020年12月31日、於2021年6月30日、於2021年7月1日及於2021年12月31日	5,000,000,000	5,000
Issued and fully paid:	已發行及悉數繳足：		
At 1 July 2020	於2020年7月1日	765,759,953	766
Shares issued in lieu of cash dividend	發行股份以代替現金股息	(a) 9,590,136	9
At 30 June 2021, at 1 July 2021, and at 31 December 2021	於2021年6月30日、於2021年7月1日及於2021年12月31日	775,350,089	775

(a) On 20 November 2020, the Company's shareholders approved at the annual general meeting a final dividend of HK2.65 cents per ordinary share payable in cash with a scrip dividend alternative ("the Scrip Dividend Scheme") for the year ended 30 June 2020 (the "2020 Final Dividend"). During the year ended 30 June 2021, 9,590,136 new shares were issued by the Company at a deemed price of HK\$1.19 per ordinary share, credited as fully paid, to shareholders of the Company who had elected to receive scrip shares in lieu of cash to settle the 2020 Final Dividend of HK\$11,412,639. The remaining balance of the 2020 Final Dividend of HK\$8,880,000 was satisfied by cash. Further details of the Scrip Dividend Scheme are set out in the Company's circular dated 14 December 2020.

17. 股本 (續)

於2020年7月1日至2021年12月31日期間，本公司的法定及已發行股本變動如下：

(a) 於2020年11月20日，本公司股東於股東週年大會上批准派發截至2020年6月30日止年度的末期股息每股普通股2.65港仙，有關股息以現金支付並附有以股代息備選方案（「以股代息計劃」）（「2020年末期股息」）。截至2021年6月30日止年度，本公司按每股普通股1.19港元的視作價格向選擇收取代息股份以代替現金的本公司股東發行9,590,136股入賬列作繳足之新股份，以支付11,412,639港元的2020年末期股息。2020年末期股息的餘額8,880,000港元已經以現金支付。以股代息計劃的進一步詳情載於日期為2020年12月14日的本公司通函。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

18. DISPOSAL OF SUBSIDIARIES

On 31 December 2021, 55% shareholding of UMP Healthcare China, an indirect non-wholly owned subsidiary of the Company, was disposed at a consideration of HK\$22 million. Further details are included in note 8 to the consolidated interim financial statements.

As at 30 June 2021, the Group classified the assets and liabilities of two subsidiaries, Health Network Medical Centre (Shatin) Limited (“HNMCL”) and 上海快驗保門診部有限公司 (“快驗保”), as assets and liabilities of disposal groups classified as held for sale.

During the period, the Group completed the disposal of its 55% and 100% equity interest of HNMCL and 快驗保 respectively.

HNMCL is engaged in the provision of general practice services and 快驗保 is engaged in the provision of health check-up services.

Upon the completion of disposal transaction of 快驗保 and HNMCL, the total gain on disposal of HK\$0.5 million was recognised in profit and loss during the period.

18. 業務合併

於2021年12月31日，本公司間接非全資附屬公司聯合醫務中國的55%股權以22百萬港元的代價出售。進一步詳情載於綜合中期財務報表附註8。

於2021年6月30日，本集團將兩間附屬公司健聯醫務中心(沙田)有限公司(「健聯」)及上海快驗保門診部有限公司(「快驗保」)的資產及負債分類為持作出售的出售組別的資產及負債。

於本期間，本集團完成出售其在健聯及快驗保的55%及100%股權。

健聯從事提供全科醫療服務而快驗保則從事提供體檢服務。

出售快驗保及健聯的交易完成後，出售總收益0.5百萬港元已在本期間的損益確認。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

19. COMMITMENTS

The Group had the following capital commitments at the end of the reporting period:

19. 承擔

於報告期末，本集團的資本承擔如下：

		31 December 2021 2021年 12月31日 HK\$'000 千港元 (Unaudited) (未經審核)	30 June 2021 2021年 6月30日 HK\$'000 千港元 (Audited) (經審核)
Contracted, but not provided for:	已訂約但未撥備：		
Leasehold improvements	租賃物業裝修	6,567	1,859
Fixtures and office equipment	裝置及辦公室設備	316	-
Medical equipment	醫療設備	204	-
Computer equipment and software	電腦設備及軟件	2,861	-
		9,948	1,859

The Group's share of capital commitments of the joint ventures not included above as follows:

並不包括在上列之本集團應佔合資公司資本承擔如下：

Contracted, but not provide for:	已訂約但未撥備	-	548
----------------------------------	---------	---	-----

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

20. RELATED PARTY TRANSACTIONS

(a) In addition to the transactions, arrangements and balances detailed elsewhere in these unaudited condensed consolidated interim financial statements, the Group had the following material transactions with related parties during the period:

20. 關聯方交易

(a) 除該等未經審核簡明綜合中期財務報表其他項目詳述的交易、安排及結餘外，本集團於期內與關聯方有以下重大交易：

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
Notes		HK\$'000	HK\$'000
附註		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Associates:			
聯營公司：			
	Administrative support fee income	144	198
	Professional services expense	1,657	1,632
	Healthcare services income	246	170
Joint ventures:			
合資公司：			
	Administrative support fee income	36	60
	Professional services expense	191	256
Related companies*:			
關聯公司*：			
	Lease payments/property rental and related expenses	3,369	3,257
	Contract healthcare solution services income	6,488	10,475

* Certain directors and/or beneficial shareholders of the Company are also directors and/or beneficial shareholders of these related companies.

* 本公司若干董事及／或實益股東亦為該等關聯公司的董事及／或實益股東。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

20. RELATED PARTY TRANSACTIONS (Continued)

(a) (Continued)

Notes:

- (i) The administrative support fee income was related to administrative support services, such as payroll services, rendered by the Group and was charged at terms mutually agreed between the relevant parties.
- (ii) The professional services expense was related to healthcare services rendered by associates, joint ventures and the related companies and was charged at terms mutually agreed between the relevant parties.
- (iii) The healthcare services income was related to medical services rendered by the Group and was charged at terms mutually agreed between the relevant parties.
- (iv) The lease payments/property rental and related expenses were related to the leasing of certain medical centres or premises for the Group's operation and were charged at terms stipulated in the respective tenancy agreements.
- (v) Contract healthcare solution services income was related to the provision of healthcare services to the employees of related companies and was charged at terms mutually agreed between the relevant parties.

20. 關聯方交易 (續)

(a) (續)

附註：

- (i) 行政支援費收入與本集團提供並按與相關方互相協定之條款收費的薪酬服務等行政支援服務有關。
- (ii) 專業服務費用與聯營公司、合資公司及關聯公司提供的醫療保健服務相關並以與相關方相互約定的條款收費。
- (iii) 醫療保健服務收入與本集團提供並按與相關方互相協定之條款收費的醫療服務有關。
- (iv) 租賃付款／物業租金及相關開支與就本集團營運租賃若干醫務中心或營運場所並按各租賃協議規定之條款收費有關。
- (v) 合約醫療保健解決方案服務收入與向關聯公司的僱員提供並按與相關方互相協定之條款收費的醫療保健服務有關。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

20. RELATED PARTY TRANSACTIONS (Continued)

(b) Other transactions with related parties

Professional services fees paid to the executive directors of the Company in relation to the rendering of healthcare services to the Group are as follows:

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Executive directors (note (i))	執行董事(附註(i))	4,607	3,377

Note:

- (i) The professional services fee related to healthcare services rendered by Dr. Sun Man Kin Michael and Dr. Lee Pak Cheung Patrick, executive directors of the Company.

20. 關聯方交易 (續)

(b) 其他關聯方交易

向本公司執行董事支付有關向本集團提供醫療保健服務的專業服務費如下：

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)

附註：

- (i) 專業服務費與本公司執行董事孫文堅醫生及李柏祥醫生提供的醫療保健服務有關。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

20. RELATED PARTY TRANSACTIONS (Continued)

(c) Compensation of key management personnel of the Group:

20. 關聯方交易 (續)

(c) 本集團主要管理人員薪酬：

		Six months ended 31 December	
		截至12月31日止六個月	
		2021	2020
		2021年	2020年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Short term employee benefits	短期僱員福利	9,059	9,302
Post-employment benefits	離職後福利	36	34
Total compensation paid to key management personnel	支付予主要管理人員的薪酬總額	9,095	9,336

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, pledged deposits, trade receivables, trade payables, the current portion of financial assets included in prepayments, other receivables and other assets, financial liabilities included in other payables and accruals, lease liabilities, balances with a joint venture, related companies and associates approximate to their carrying amounts largely due to the short term maturities/no fixed terms of repayments of these instruments or the effect of discounting is not material.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of the non-current portion of lease liabilities have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities.

The fair values of listed equity and debt investments are based on quoted market prices.

21. 金融工具的公允價值及公允價值等級

經管理層評估，現金及現金等價物、已抵押存款、貿易應收款項、貿易應付款項、計入預付款項、其他應收款項及其他資產的金融資產的流動部分、計入其他應付款項及應計費用的金融負債、租賃負債、與一間合資公司、關聯公司及聯營公司結餘的公允價值與賬面值相若，主要因該等工具之到期時間較短／無固定償還期限或貼現影響並不重大。

金融資產及負債的公允價值按自願交易方（而非強迫或清盤銷售）於當前交易中交換該工具的金額入賬。

租賃負債非流動部分的公允價值乃採用現時可得年期、信貸風險及剩餘期限類似的工具的息率貼現預期未來現金流量而計算。

上市股權及債務投資的公允價值基於公開市場報價釐定。

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

The fair values of unlisted equity investments, a contingent receivable and derivative financial instrument have been estimated using either valuation techniques based on discounted cashflow method or based on recent market transaction prices.

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 31 December 2021 (unaudited)

21. 金融工具的公允價值及公允價值等級 (續)

非上市股本投資、一項或有應收款項及衍生金融工具的公允價值按已貼現現金流量方法或按最近市場交易價格的估值法估計。

公允價值等級

下表載列本集團金融工具的公允價值計量等級：

按公允價值計量的資產：

於2021年12月31日(未經審核)

		Fair value measurement using			Total
		Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	
		活躍市場報價 (第一級)	重大可觀察輸入數據 (第二級)	重大不可觀察輸入數據 (第三級)	總計
		HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元
Investments at fair value through other comprehensive income:	按公允價值計入其他全面收入的投資：				
– Unlisted equity investments	– 非上市股本投資	–	–	4,901	4,901
– Listed equity investments	– 上市股本投資	22,066	–	–	22,066
Financial assets at fair value through profit or loss	按公允價值計入損益的金融資產	1,691	30,116	–	31,807
		23,757	30,116	4,901	58,774

Notes to the Condensed Consolidated Interim Financial Statements

簡明綜合中期財務報表附註

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Assets measured at fair value: (Continued)

As at 30 June 2021 (audited)

		Fair value measurement using 公允價值計量採用的基準			
		Quoted prices in active markets (Level 1) 活躍市場 報價 (第一層) HK\$'000 千港元	Significant observable inputs (Level 2) 重大可觀察 輸入數據 (第二層) HK\$'000 千港元	Significant unobservable inputs (Level 3) 重大不可觀察 輸入數據 (第三層) HK\$'000 千港元	Total 合計 HK\$'000 千港元
Investments at fair value through other comprehensive income:	按公允價值計入其他全面收入的投資：				
- Unlisted equity investments	- 非上市股本投資	-	-	5,367	5,367
- Listed equity investments	- 上市股本投資	18,236	-	-	18,236
Financial assets at fair value through profit or loss	按公允價值計入損益的金融資產	1,852	25,263	-	27,115
		20,088	25,263	5,367	50,718

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for financial assets and financial liabilities (six months ended 31 December 2020: Nil).

於期內，金融資產及金融負債第一層與第二層之間並無公允價值計量轉撥，亦無轉至或轉出第三層（截至2020年12月31日止六個月：無）。

22. APPROVAL OF THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The unaudited condensed consolidated interim financial statements were approved and authorised for issue by the Board on 24 February 2022.

22. 批准未經審核簡明綜合中期財務報表

未經審核簡明綜合中期財務報表已於2022年2月24日獲董事會批准及授權刊發。

<p>“1HFY2021” 「2021財政年度上半年」</p>	<p>six months ended 31 December 2020; 截至2020年12月31日止六個月；</p>
<p>“1HFY2022” 「2022財政年度上半年」</p>	<p>six months ended 31 December 2021; 截至2021年12月31日止六個月；</p>
<p>“Affiliated Clinic(s)” 「聯屬診所」</p>	<p>clinic(s) which is/are not operated by the Group but which has entered or will enter into an agreement directly with the Group to offer Medical Services, Dental Services and/or Auxiliary Services to the Plan Members; 並非由本集團經營但已經或將直接與本集團訂立協議的診所，據此向計劃成員提供醫療服務、牙科服務及／或輔助服務；</p>
<p>“Affiliated Doctor(s)”, “Affiliated Dentist(s)” or “Affiliated Auxiliary Services Provider(s)” 「聯屬醫生」、「聯屬牙醫」或「聯屬輔助服務提供者」</p>	<p>doctor(s)/dentist(s)/auxiliary services provider(s) who has entered or will enter into an agreement directly with the Group to provide services to Plan Members and who, in accordance with the terms of such agreement, has received or will receive an amount from the Group based on the volume of Plan Members treated; 已經或將直接與本集團訂立協議提供服務予計劃成員的醫生／牙醫／輔助服務提供者，根據該等協議條款，彼等已經或將按接診的計劃成員數目向本集團收取款項；</p>
<p>“Audit Committee” 「審核委員會」</p>	<p>the audit committee of the Board; 董事會轄下審核委員會；</p>
<p>“Auxiliary Services” 「輔助服務」</p>	<p>includes imaging and laboratory services, physiotherapy, traditional Chinese medicine, vision care and optometry and child health assessment; 包括醫學影像及化驗服務、物理治療、中醫、眼科護理及驗光以及兒童健康發展評估；</p>
<p>“Auxiliary Services Provider(s)” 「輔助服務提供者」</p>	<p>auxiliary services provider(s) who is/are or will be engaged directly by the Group as a consultant to provide Auxiliary Services in the UMP Medical Centres in accordance with the terms of a consultancy agreement with the Group, and the Affiliated Auxiliary Service Providers; 已經或將直接受本集團委聘為顧問以根據與本集團簽訂的顧問協議的條款在聯合醫務中心內提供輔助服務的輔助服務提供者，以及聯屬輔助服務提供者；</p>
<p>“Board” 「董事會」</p>	<p>the board of Directors of the Company; 本公司董事會；</p>
<p>“Code of Conduct for Securities Transactions by Employees” 「僱員進行證券交易的操守準則」</p>	<p>the Code of Conduct for Securities Transactions by Employees as adopted by the Company; 本公司所採納僱員進行證券交易的操守準則；</p>

Glossary 詞彙

“Company” or “UMP” 「本公司」或「聯合醫務」	UMP Healthcare Holdings Limited, a company incorporated under the laws of the Cayman Islands with limited liability, the shares of which are listed on the main board of the Hong Kong Stock Exchange (stock code: 722); 聯合醫務集團有限公司，一間根據開曼群島法律註冊成立的有限公司，其股份於香港聯交所主板上市(股份代號：722)；
“Contract Customers” 「合約客戶」	collectively, insurance companies and corporations which have entered or will enter into corporate plans with the Group for healthcare benefits for Plan Members; 就計劃成員醫療保健福利已經或將與本集團訂立企業計劃的保險公司及企業的統稱；
“Corporate Governance Code” 「企業管治守則」	the Corporate Governance Code as set out in Appendix 14 to the Listing Rules; 上市規則附錄十四所載企業管治守則；
“COVID-19” 「新型冠狀病毒」	means coronavirus disease 2019, a disease caused by a novel virus designated as severe acute respiratory syndrome coronavirus 2; 2019冠狀病毒疾病，一種由被稱為嚴重急性呼吸系統綜合症冠狀病毒2的新型病毒引起的疾病；
“CR Medical” 「華潤醫療」	China Resources Medical Holdings Company Limited, a company incorporated in the Cayman Islands with limited liability and listed on the Main Board of the Hong Kong Stock Exchange (stock code: 1515); 華潤醫療控股有限公司，一間在開曼群島註冊成立並在香港聯交所主板上市的公司(股份代號：1515)；
“Dental Services” 「牙科服務」	include primary dental services such as scaling and polishing and secondary dental services such as crown and bridge, orthodontics, implants and whitening; 包括基本牙科服務(如洗牙及拋光)以及第二層牙科服務(如牙冠及牙橋、口腔正畸、植齒及牙齒美白)；
“Dentist(s)” 「牙醫」	dentist(s) who is/are or will be engaged directly by the Group as a consultant to provide Dental Services in the UMP Medical Centres in accordance with the terms of a consultancy agreement with the Group, and the Affiliated Dentists; 已經或將直接受本集團委聘為顧問以根據與本集團簽訂的顧問協議的條款在聯合醫務中心內提供服務的牙醫，以及聯屬牙醫；
“Director(s)” 「董事」	the director(s) of the Company; 本公司董事；

“Doctor(s)” 「醫生」	doctor(s) who is/are or will be engaged directly by the Group as a consultant to provide Medical Services in the UMP Medical Centres in accordance with the terms of a consultancy agreement with the Group, and the Affiliated Doctors; 已經或將直接受本集團委聘為顧問以根據與本集團簽訂的顧問協議的條款在聯合醫務中心內提供服務的醫生，以及聯屬醫生；
“FY2021” 「2021財政年度」	the year ended 30 June 2021; 截至2021年6月30日止年度；
“general practitioner” or “general practice” 「全科醫生」或「全科醫療」	doctors trained in general practice and best suited to act as first point of contact for patients, having the required knowledge to refer patients to the appropriate specialists or services as required; 接受全科訓練的醫生，最適合為患者提供首次診斷，已具備按需要轉介患者至適合專科或服務所需的知識；
“Global Offering” 「全球發售」	the offer of the shares of the Company to the public in Hong Kong and outside the United States of America in offshore transactions in reliance on Regulation S, the details of which are set out in “Structure of the Global Offering” of the Prospectus; 本公司向香港公眾人士及依據S規例在美國境外的離岸交易中發售股份，詳情載於招股章程「全球發售的架構」；
“Group”, “we”, “our” or “us” 「本集團」或「我們」	the Company and its subsidiaries; 本公司及其附屬公司；
“Healthcare Ventures” 「醫療創業控股」	Healthcare Ventures Holdings Limited, a company incorporated under the laws of British Virgin Islands with limited liability, which is a substantial shareholder of the Company and wholly-owned subsidiary of Chow Tai Fook Enterprises Limited; 醫療創業控股有限公司，一間根據英屬處女群島法律註冊成立的有限公司，為本公司的主要股東及周大福企業有限公司的全資附屬公司；
“HK\$” 「港元」	Hong Kong dollars, the lawful currency of Hong Kong; 香港法定貨幣港元；
“Hong Kong” 「香港」	Hong Kong Special Administrative Region of the PRC; 中國香港特別行政區；
“Hong Kong & Macau Clinical Healthcare Services” 「香港及澳門臨床醫療保健服務」	provision of clinical healthcare services to Self-paid Patients; 向自費患者提供臨床醫療保健服務；

Glossary 詞彙

“Hong Kong & Macau Corporate Healthcare Solution Services” 「香港及澳門企業醫療保健解決方案服務」	provision of corporate healthcare solutions to Contract Customers; 向合約客戶提供企業醫療保健解決方案；
“Hong Kong Stock Exchange” or “Stock Exchange” 「香港聯交所」或「聯交所」	The Stock Exchange of Hong Kong Limited; 香港聯合交易所有限公司；
“Listing Rules” 「上市規則」	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange; 香港聯交所證券上市規則；
“Macau” 「澳門」	the Macau Special Administrative Region of the PRC; 中國澳門特別行政區；
“Mainland China” or “PRC” 「中國內地」或「中國」	the People’s Republic of China (excluding, for the purpose of this report, Hong Kong, Macau and Taiwan); 中華人民共和國(就本報告而言，不包括香港、澳門及台灣)；
“Mainland China Clinical Healthcare Business” 「中國內地臨床醫療保健業務」	consists of (i) health check-up business; and (ii) selected outpatient services such as family medicine within the clinics we own and operate; 包括(i)體檢業務；及(ii)在我們擁有及營運的診所內提供選定門診服務(如家庭醫學)；
“Medical” or “Medical Services” 「醫療」或「醫療服務」	includes general practice and specialist practice; 包括全科醫療及專科醫療；
“Model Code” 「標準守則」	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules; 上市規則附錄10所載上市發行人董事進行證券交易的標準守則；
“Plan Members” 「計劃成員」	members of the Group’s corporate healthcare benefits plans, who typically include group medical insurance policyholders and employees of corporations and/or their dependants; 本集團企業醫療保健福利計劃成員，一般包括集團醫療保險保單持有人及機構的僱員及／或彼等之受養人；

“Post-IPO Share Option Scheme” 「首次公開發售後購股權計劃」	the post-IPO share option scheme approved and adopted by the Company on 2 November 2015; 本公司於2015年11月2日批准及採納的首次公開發售後購股權計劃；
“Pre-IPO Share Option Scheme” 「首次公開發售前購股權計劃」	the pre-IPO share option scheme approved and adopted by the Board on 18 August 2015; 董事會於2015年8月18日批准及採納的首次公開發售前購股權計劃；
“Prospectus” 「招股章程」	the prospectus of the Company dated 17 November 2015; 日期為2015年11月17日的本公司招股章程；
“Remuneration Committee” 「薪酬委員會」	the remuneration committee of the Board; 董事會薪酬委員會；
“Share(s)” 「股份」	ordinary share(s) with a nominal value of HK\$0.001 each in the share capital of the Company; 本公司股本中每股面值0.001港元的普通股
“Self-paid Patients” 「自費患者」	patients who visit a UMP Medical Centre operated by the Group and pay for services using cash or credit card; 到本集團經營的聯合醫務中心就診並使用現金或信用卡支付服務費用的患者；
“SFO” 「證券及期貨條例」	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended and supplemented from time to time; 香港法例第571章《證券及期貨條例》，經不時修訂及補充；
“Share(s)” 「股份」	ordinary share(s) with a nominal value of HK\$0.001 each in the share capital of the Company; 本公司股本中每股面值0.001港元之普通股；
“Share Award Scheme” 「股份獎勵計劃」	the share award scheme approved and adopted by the Board on 30 June 2016; 董事會於2016年6月30日所批准及採納的股份獎勵計劃；
“specialist practice” or “specialist services” 「專科醫療」或「專科服務」	a range of specialist practice, including Family Medicine, Internal Medicine, Surgery, Paediatrics, Cardiology, Dermatology, Otorhinolaryngology, Orthopaedics, Ophthalmology, Urology, Gastroenterology and Hepatology, Radiology, Endocrinology and Diabetes. Please see www.ump.com.hk for the updated list of specialist practices; 一系列專科醫療，包括家庭醫學科、內科、外科、兒科、心臟科、皮膚科、耳鼻喉科、骨科、眼科、泌尿科、腸胃肝臟科、放射科、內分泌及糖尿病科等。專科醫療之經更新清單請參閱 www.ump.com.hk ；



Glossary 詞彙

“UMP Medical Centre(s)” 「聯合醫務中心」	medical centre(s) offering Medical Services, Dental Services and/or Auxiliary Services which is operated by the Group; and 提供醫療服務、牙科服務及／或輔助服務的醫務中心，由本集團經營；及
“UMP Network” 「UMP網絡」	consists of (i) UMP Medical Centres which are operated by the Group and (ii) Affiliated Clinics which are clinics not operated by the Group but which has entered into an agreement with the Group to offer Medical Services, Dental Services and/or Auxiliary Services to Plan Members. 包括(i)本集團經營的聯合醫務中心及(ii)聯屬診所(並非由本集團經營的診所，但已與本集團訂立協議向計劃成員提供醫療服務、牙科服務及／或輔助服務)。



✉ : business@ump.com.hk
 ☎ : (+852) 2824 0231
 📞 : (+852) 2511 1152
 🌐 : <https://www.ump.com.hk>

UMP Healthcare Official
Youtube Channel

